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1.1 Definition and epidemiology of pain in general and of neuropathic pain 
in particular 
Pain is defined as an unpleasant sensory and emotional experience associated with 
actual or potential tissue damage, or described in terms of such damage [1]. In the 
clinical setting, three types of pain are distinguished: nociceptive, visceral and neuro-
pathic pain. 
 Nociceptive pain arises from actual or threatening damage to non-neuronal 
tissues and is caused by the activation of nociceptors. It is transmitted through normal 
peripheral and central pain pathways and functions as a warning signal for actual or 
potential tissue injury thus eliciting a protective response. It tends to be of short 
duration, has an identifiable cause and is focal to the site of injury. Generally, nocicep-
tive pain responds well to treatment and has a good prognosis [1]. 
 Visceral pain originates from some but not all of the internal organs. Key features 
include a diffuse localization, an unreliable association with injury, referred sensations 
and an association with motor and autonomic reflexes. Pathways for visceral nocicep-
tion are diffusely organized and include the vagus nerve, sympathetic efferent fiber 
pathways and the pelvic nerve. Healthy visceral tissues evoke minimal sensations. 
However, in the presence of inflammation silent primary afferent nerve fibers become 
very mechanically sensitive and highly responsive to other stimuli [2]. 
 The third type of pain, neuropathic pain, is caused by a lesion of the somatosenso-
ry nervous system [3]. It is a chronic condition persisting beyond the point of tissue 
healing. Therefore, it seems to serve no biological function and, generally, has a poor 
response to treatment. Already in 1564, Ambroise Paré gave a detailed description of a 
form of neuropathic pain associated with limb amputation [4], a condition that 300 
years later was termed ‘phantom limb pain’ by Silas Weir Mitchell [5]. Mitchell ob-
served clinical signs associated with major nerve damage such as hyperalgesia (an 
exaggerated response to a normally painful stimulus) and allodynia (pain caused by a 
normally non-painful stimulus). Besides these stimulus-evoked pain sensations, spon-
taneous pain is also often present and described by patients as burning, throbbing or 
shooting [6]. At present, neuropathic pain is still defined in similar terms as those used 
by Paré and Mitchell: “pain arising as a direct consequence of a lesion or disease 
affecting the somatosensory system” [3]. Depending on where the lesion or dysfunc-
tion occurs in the somatosensory system, neuropathic pain can be peripheral or 
central in origin. The etiology of the nerve damage leading to neuropathic pain is 
diverse and may include infection, trauma, nerve compression, neurotoxins, metabolic 
diseases, radiation, inflammation, and tumor infiltration. A recent review of epidemio-
logical studies concerning neuropathic pain estimates the prevalence of chronic pain 
with neuropathic characteristics between 6.9 and 10% in the general population [7]. 
Although studied for centuries, neuropathic pain still has a major impact on patients 
and society: neuropathic pain patients experience a poor health-related quality of life 
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and consume a high number of healthcare resources and costs [8, 9]. In the United 
States, chronic pain affects 100 million adults and costs ca. 600 billion US dollars 
annually. These costs exceed those of the 6 major health conditions in the US (cardio-
vascular diseases, neoplasms, injury and poisoning, endocrine, nutritional and meta-
bolic diseases, digestive system diseases, and respiratory system diseases) [10]. The 
high prevalence of neuropathic pain in combination with a poor response to current 
treatments make research of neuropathic pain challenging and an absolute necessity 
for successful pain therapy. 
1.2 Pathophysiology of neuropathic pain 
In order to grasp the pathophysiology of neuropathic pain, we first need to look at the 
basic pain signalling pathway. This pathway consists of several elements that collabo-
rate to transmit painful stimuli to the brain [11, 12] (Fig. 1): 
1. Primary afferent nociceptors (PAN) consisting of Aδ- en C-nerve fibers, which 
transduce mechanical, chemical and thermal nociceptive stimuli into electrical ac-
tivity and transmit this information to the dorsal horn. 
2. Excitatory and inhibitory second order neurons in laminae I, II and V of the dorsal 
horn of the spinal cord, which integrate and modulate PAN information and 
transmit this information to supraspinal centers. 
3. Several ascending pathways conduct this pain information to higher brain centers: 
the lateral spinothalamic tract (discriminative aspect of pain) and the spino-
parabrachio-amygdaloid and the spino-parabrachio-hypothalamic pathways (emo-
tional-cognitive aspects of pain). 
4. In the brain, the ventroposterolateral and ventroposteromedial thalamic nuclei 
integrate the sensory discriminative elements of pain and transmit this nocicep-
tive information to the primary somatosensory cortex. 
5. Furthermore, the ventromedular and ventroposterioinferior thalamic nuclei 
transmit affective-cognitive information to the secondary somatosensory cortex, 
the inferior parietal cortex, the anterior cingulate cortex, the prefrontal cortex 
and the insular cortex. 
6. Finally, cortico-limbic structures integrate pain sensation and pain affect. 
Conversely, descending inhibitory pathways originating in the peri-aqueductal grey, 
locus coeruleus and nucleus raphe magnus reduce pain transmission in the dorsal horn 
of the spinal cord via the rostroventromedial medulla and the dorsolateral pontine 
tegmentum. 
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Figure 1. The pain signalling pathway. Illustration: Rogier Trompert, Medical Art. 
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Neuropathic pain ensues from sensitization within this basic pain pathway. Peripheral 
sensitization is caused by increased responsiveness and reduced thresholds to the 
stimulation of the receptive fields of nociceptive neurons in the periphery, whereas 
central sensitization comes from increased responsiveness to either normal or sub-
threshold afferent input of central nociceptive neurons [1]. Increased neuronal re-
sponsiveness and reduced stimulation thresholds result from increased ligand-receptor 
interactions, from the expression of new ion channels and receptors, from the in-
creased synaptic release of neurochemical messengers, from the activation of glial 
cells, and from a reduction of inhibitory signals (disinhibition). This sensitization results 
in facilitation of pain transmission throughout the pain signalling pathway. The differ-
ent contributors to peripheral and central sensitization are summarized in Figures 2 A 
and B, respectively. 
 
 
Figure 2, panel A. Peripheral sensitization. Illustration: Rogier Trompert, Medical Art. 
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Figure 2, panel B. Central sensitization. Illustration: Rogier Trompert, Medical Art. 
NOS: nitric oxide synthase; TLR4: toll-like receptor 4; CCL2: CC chemokine ligand 2; GRK2: G protein-coupled 
receptor kinase 2; CREB: cyclic AMP response element binding protein; IL18: interleukin 18; IL1β: interleukin 
1β; IL6: interleukin 6; p38-MAPK: p38 mitogen-activated protein kinase; P2X4: purinergic receptor; KCC2: 
potassium chloride exporter 2; TrkB: tyrosine kinase receptor B; mGluR5: metabotrope glutamate receptor
5; ATP: adenosine-5’-triphosphate; VDCC: voltage-dependent calcium channel; TNF-α: tumor necrosis factor 
α, INF-γ: interferon γ; Glu: glutamate; SP: substance P; CGRP: calcitonin gene-related peptide; NMDA: N-
methyl-D-aspartate receptor; AMPA: α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor; NK1: 
neurokinin receptor 1; NKA: neurokinin A; Nav 1.3: voltage-dependent sodium channel 1.3; NGF: nerve 
growth factor; TRPV1: transient receptor potential vanilloid 1; ASIC: acid-sensing ion channel. 
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1.3 Scientific background of the thesis research 
The aim of this thesis research is to identify new targets and biological indicators 
(‘biomarkers’) and to contribute to the development of better treatments of neuro-
pathic pain arising from a central or from a peripheral lesion (Fig. 3). 
 
 
Figure 3. Schematic outline of the focus and studies described in this thesis 
BDNF: brain-derived neurotrophic factor; CGRP: calcitonin gene-related peptide; NPY: neuropeptide Y; TNF-
α: tumor necrosis factor α; GABA: γ-aminobutyric acid. 
1.3.1 Lumbosacral radicular pain as a model for central neuropathic pain 
Lumbosacral radicular pain is characterized by pain radiating into one or more lumbar 
and/or sacral dermatomes and may be accompanied by signs of radiculopathy (de-
creased motor or sensory function) or radicular irritation [13]. Lumbosacral radicular 
pain is much more prevalent (780-7600/100,000 population) than post-herpetic 
neuralgia (10-185/100,000 population), diabetic neuropathy (50-1.140/100,000 popu-
lation) or complex regional pain syndrome (5-50/100,000 population) [14-16]. Never-
theless, it is among the least researched conditions with regard to neuropathic pain 
[9]. Furthermore, controversy exists as to the best pharmacological treatment of this 
condition. For these reasons, for our human research on neuropathic pain with a 
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central origin, we selected lumbosacral radicular pain as our model for central neuro-
pathic pain. 
1.3.2 Occipital neuralgia as a model of peripheral neuropathic pain 
Another model we have used in our research on neuropathic pain is occipital neural-
gia. This is a sudden non-throbbing, stabbing pain in the area of the greater or lesser 
occipital nerve. Tendinomuscular compression of the occipital nerves in the region of 
the occiput is the most frequent etiology [17]. The pain is located in the suboccipital 
region, radiates over the scalp and can be elicited by applying pressure over the course 
of the greater or lesser occipital nerve. Hypo- or dysesthesia may be present. These 
symptoms in combination with a short-term improvement after local anesthetic 
infiltration establish the diagnosis of occipital neuralgia [18]. These well-defined 
diagnostic criteria combined with the fact that the course of the greater and lesser 
occipital nerves has been very well-studied [19-22], make occipital neuralgia an ideal 
research model for neuropathic pain. With this model we will study the effect of 
pulsed radiofrequency current (PRF) on neuropathic pain with a peripheral origin. 
1.3.3 Brain-derived neurotrophic factor as a key target for the treatment of neuro-
pathic pain 
Several neurochemical messengers have been implicated in the generation of neuro-
pathic pain (Fig. 2). Among these, neurotrophins play key roles in generating and 
maintaining this type of pain [23-25]. Brain-derived neurotrophic factor (BDNF) de-
serves special attention because in recent years it emerged as a modulator of central 
and peripheral pain responses in spinal and peripheral nerve injury models. BDNF was 
the second neurotrophin to be discovered [26] and it belongs, together with nerve 
growth factor, neurotrophin 3 and neurotrophin-4/5, to the neurotrophin superfamily 
that supports the survival of specific populations of embryonic neurons. The neurotro-
phins interact with two kinds of cell surface receptor, viz. with the Trk family of high 
affinity tyrosine kinase receptors and with the low-affinity p75 neurotrophin receptor 
(p75NTR). Whereas all neurotrophins bind the p75NTR receptor, nerve growth factor 
binds the TrkA receptor, BDNF and neurotrophin-4/5 bind the TrkB receptor and 
neurotrophin 3 binds the TrkC receptor. Although in adulthood neurons no longer 
remain dependent on these neurotrophins for their survival, neurotrophins still take 
part in crucial neural functions such as learning, memory and regulation of food intake 
[27, 28]. 
 A number of animal models for chronic and neuropathic pain allow us to investi-
gate different pain pathways and these neurotrophins under controlled experimental 
conditions. A prerequisite for a good model is that it mimics signs and symptoms 
associated with neuropathic pain in humans. For our laboratory studies we have 
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chosen the ‘sciatic chronic constriction injury model’ as described by Bennett and Xie 
[29] because it reliably induces allodynia, hyperalgesia and spontaneous pain. 
 Thanks to animal research, the involvement of BDNF in the generation and 
maintenance of neuropathic pain has become evident. This, however, does not mean 
that BDNF’s role in this phenomenon is fully understood. In animal models of neuro-
pathic pain, different lesions give rise to different patterns of BDNF expression at the 
lesion site, in the dorsal root ganglion and in the dorsal horn [25]. Moreover, pain is no 
longer the sole prerogative of neurons. Recently, microglia was found to initiate 
neuropathic pain and BDNF appears to be a crucial messenger in the crosstalk between 
neurons and microglia [30, 31]. Microglia, by way of IL-18, also entangles astrocytes in 
the late phase of neuropathic pain, a situation that might contribute to the mainte-
nance of this pain [32]. As a consequence, inhibition of BDNF expression could repre-
sent an important novel step in the therapy of neuropathic pain. In order for BDNF to 
be a useful new target it is, however, necessary to ascertain that existing drugs for the 
treatment of neuropathic pain do not exert their function through inhibition of BDNF. 
1.3.4 Minocycline as a new treatment for central neuropathic pain 
Pharmacological management of lumbosacral radicular pain is derived from therapies 
of other neuropathic conditions such as diabetic polyneuropathy and postherpetic 
neuralgia. The latter treatments involve the increase of spinal serotonin and norepi-
nephrine levels by administering tricyclic antidepressants such as amitriptyline and 
dual serotonin and norepinephrine reuptake inhibitors, or by reducing glutamate and 
substance P release by blocking the α2-δ subunit of voltage-gated calcium channels 
with gabapentin or pregabalin [33-35]. However, in randomized trials less than 50% of 
patients achieve adequate pain relief [36] and side-effects arising from these drugs 
often prohibit their use. Moreover, drugs effective in diabetic polyneuropathy and 
postherpetic neuralgia have failed to demonstrate superiority over placebo treatment 
of lumbosacral radicular neuropathic pain [37-39]. Consequently, there is a strong 
need for novel drugs and targets to improve current treatment of this type of neuro-
pathic pain. 
 Minocycline attenuates mechanical allodynia and thermal hyperalgesia in rodent 
models for neuropathic pain when administered pre-emptively by inhibiting pain 
signalling in spinal microglia and dorsal horn neurons [40, 41]. Although beneficial 
effects of minocycline have been observed in the neurological and functional recovery 
of patients with stroke [42], spinal cord injury [43] and multiple sclerosis [44], the 
usefulness of this drug in the treatment of neuropathic pain in humans has never been 
investigated before. 
G E N E R A L  I N T R O D U C T I O N  
 19
1.3.5 Pulsed radiofrequency current as a treatment for peripheral neuropathic pain 
For centuries electric current has been used to treat pain. In ancient Greece and Rome, 
pain due to gout was treated by placing patients in pools with electric eels until their 
feet went numb. The first controlled use of electricity in human pain treatment dates 
back to 1931 and concerns the treatment of trigeminal neuralgia [45]. To obtain more 
predictable lesion sizes, the application of radiofrequency electric current was advo-
cated [46]. The initial assumption that heat and subsequent coagulation of nerve fibres 
would be responsible for interference with nerve conduction and analgesia [47] was 
rejected on the basis of the finding that no difference in outcome was seen when 
comparing two different temperatures (40°C and 67°C) applied to the cervical dorsal 
root ganglion to treat chronic cervical radicular pain [48]. Subsequently, a technique 
was developed in which the electrode temperature was kept below the neurodestruc-
tive 42°C by allowing a washout period of 480 ms after a 20 ms burst of radiofrequency 
current. PRF can be successful in the treatment of chronic radicular pain when applied 
at the dorsal root ganglion in well-selected patient groups [49-51]. Lesions of peripher-
al nerves often result in neuropathic pain in the nerves’ dermatomal distribution areas. 
Because blocking peripheral nerves with local anesthetics provides only temporary 
pain relief, other treatments are necessary for long-term analgesia. PRF is advocated 
as a minimally destructive neuromodulatory therapy [52] ideal for use in the presence 
of non-malignant neuropathic pain. PRF at the very site of peripheral nerve injury has 
mainly been reported in case reports [53-57]. Only one retrospective study demon-
strated superiority of PRF at the level of the thoracic dorsal root ganglion (DRG) over 
PRF at the intercostal nerve for chronic postsurgical thoracic pain [58]. However, when 
different spinal nerves contribute to the formation of one peripheral nerve or when 
approaching the DRG may be dangerous, it seems logical to target the peripheral nerve 
rather than to act upon multiple spinal DRG’s with the risk of serious complications. 
1.3.6 Biological indicators for neuropathic pain 
Not only is there a void in the treatment of neuropathic pain, there are also no biologi-
cal indicators available that allow for diagnosing neuropathic pain or for monitoring 
the effect of neuropathic pain treatment. Biological indicators are defined as ‘any 
characteristic that is objectively measured and evaluated as an indicator of normal 
biological processes, pathogenic processes, or pharmacologic responses to a therapeu-
tic intervention’ [59]. This ‘open’ approach has permitted cardiologists to diagnose 
myocardial ischemia or infarction in at least five different ways: 
1. Biochemically, by measuring cardiac enzymes 
2. Electrically, by electrocardiogram 
3. By ultrasound (echocardiography) 
4. With radio-isotopes (myocardscintigraphy) 
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5. By cardiac and coronary catheterization 
However, in pain medicine, physicians still rely on rather subjective questionnaires to 
clinically detect or differentiate between various forms of pain, in spite of the vast 
current knowledge of multiple biochemical pathways with their numerous signalling 
molecules that have been uncovered through animal research. Imaging studies such as 
functional magnetic resonance imaging [60, 61], positron emission tomography [62] 
and proton magnetic resonance spectroscopy [63] are emerging as promising new 
tools to detect chronic and neuropathic pain. These techniques demonstrate biochem-
ical changes in various brain regions associated with pain processing. However, due to 
their time-consuming nature and expensiveness, they have not found their way into 
daily clinical practice. It would enhance the clinical practice if the biochemical sub-
stances detected by these techniques could be measured more easily in blood and 
cerebrospinal fluid. As the perception and expression of pain appears to be the result 
of complex processes that are influenced by emotions and cognitions that change its 
perception and expression, biological indicators will probably not permit us to accu-
rately measure the degree of pain patients perceive. Nevertheless, we can search for 
biological indicators that qualitatively distinguish nociceptive from neuropathic pain. In 
addition, the use of biological indicators in humans can give us, albeit indirect, insight 
into the mechanisms underlying tissue damage, nerve injury and neuropathic pain 
because direct spinal or nerve tissue sampling as performed in animal research would 
lead to the neuropathic pain condition that we are trying to treat. Therefore, in this 
thesis research we have investigated the concentrations of key molecules known to 
participate in the generation and maintenance of neuropathic pain in the blood and 
cerebrospinal fluid of patients suffering from neuropathic pain. 
1.4 Research questions 
In this thesis, the following research questions have been addressed: 
• What is the role of BDNF in animals suffering from neuropathic pain? 
• Do amitriptyline, gabapentin and minocycline reduce neuropathic pain behavior in 
a rat chronic constriction injury model via BDNF? 
• Can minocycline and amitriptyline reduce lumbosacral radicular pain in humans? 
• What is the current state of the art concerning occipital neuralgia? 
• Can PRF at the level of the occipital nerves reduce neuropathic pain in occipital 
neuralgia? 
• Can neurotransmitters and other neurochemical messengers be used as biological 
indicators for neuropathic pain? 
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1.5 Outline of this thesis 
In Chapter 2 an overview will be given of the scientific evidence that BDNF is involved 
in the generation of neuropathic pain in various animal models. 
 
In Chapter 3 we will report on an investigation on the effects of current medical 
therapies on neuropathic pain behavior in rats and their possible actions on BDNF 
expression in the spinal dorsal horn. 
 
Chapter 4 describes how the findings of our animal research have been used in a 
clinical trial, studying the effect of minocycline and amitriptyline on lumbosacral 
radicular pain in humans. 
 
Chapter 5 is a review of the state of the art regarding occipital neuralgia and its treat-
ment. 
 
In Chapter 6 the effects of PRF on occipital neuralgia, as a model of peripheral neuro-
pathic pain, will be presented. 
 
In Chapter 7 neurochemical messengers involved in the generation and maintenance 
of neuropathic pain will be examined for their usefulness as biological indicators. 
 
In Chapter 8 we will discuss the results of this thesis research in a broad and integrated 
scientific context, and several suggestions for future research will be given. 
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Abstract 
Even in present day pain therapy, neuropathic pain remains a challenge for clinicians 
to treat and a challenge for researchers to investigate. Different animal models have 
been developed to mimic neuropathic pain. Neurotrophins such as nerve growth 
factor, brain-derived neurotrophic factor and neurotrophin 3 have been studied 
extensively in these models, yet few review articles concerning brain-derived neu-
rotrophic factor have been published. This article reassesses the literature concerning 
brain-derived neurotrophic factor expression in the sciatic nerve chronic constriction 
injury model, the sciatic nerve transection model, the spinal nerve ligation model and 
the spinal nerve transection model and discusses differences in regulation of brain-
derived neurotrophic factor between these models and their causality with neuro-
pathic pain. 
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2.1 Introduction 
Neuropathic pain is caused by diseases or trauma to the central or peripheral nervous 
system [1]. With an estimated prevalence of 1.5%, the burden of neuropathic pain on 
patients and healthcare systems appears to be potentially large: neuropathic pain 
patients experience a poor health-related quality of life and consume a high level of 
healthcare resources and costs [2, 3]. Devoid of specific drug therapy and poorly 
responsive to traditional pain medication [4] this condition still embodies a challenge 
to researchers and clinicians [5]. A number of animal models for chronic neuropathic 
pain have been established and validated: chronic constriction injury (CCI) of the sciatic 
nerve [6], partial sciatic nerve ligation [7], L5 and L6 spinal nerve ligation (SNL) [8], 
sciatic nerve transection [9], L5 spinal nerve transection [10] and spared nerve injury 
[11]. Neurotrophins play key roles in neuropathic pain [12, 13] and are researched 
extensively in these animal models. Brain-derived neurotrophic factor (BDNF) was the 
second neurotrophin to be uncovered in 1980 [14]. Together with nerve growth factor 
(NGF), neurotrophin 3 (NT3) and neurotrophin 4/5 (NT4/5), BDNF belongs to the 
neurotrophin superfamily that supports the survival of specific populations of embry-
onic neurons. The neurotrophins interact with two categories of cell surface receptors: 
the Trk family of high affinity tyrosine kinase receptors and the low-affinity p75 neuro-
trophin receptor (p75NTR). Whereas all neurotrophins bind the p75NTR receptor, NGF 
binds TrkA receptors, BDNF and NT-4/5 bind TrkB receptors and NT3 binds TrkC recep-
tors. Although in adulthood neurons no longer remain dependent on these neurotro-
phins for their survival, neurotrophins still take part in important neuronal functions 
such as learning, memory [15] and food intake [16]. In recent years BDNF emerged as a 
modulator of central and peripheral nociceptive responses. In a general review about 
BDNF, Merighi [17] concluded that the role of BDNF in inflammatory pain models is 
well defined, although due to the multiplicity of experimental approaches, the correla-
tion between BDNF and neuropathic pain is still unclear. The present review article 
concentrates on the sciatic nerve chronic constriction injury model, the sciatic nerve 
transection model, the spinal nerve ligation model and the spinal nerve transection 
model as models for neuropathic pain and categorizes the current literature about the 
expression of BDNF in the peripheral nerve, dorsal root ganglion and dorsal horn with 
emphasis on the site and type of nerve lesion used to mimic neuropathic pain. The 
type of neurons and intracellular transduction pathways thought to be involved in the 
expression of BDNF will be reviewed. 
2.2 Literature Search Methods 
A Medline (PUBMED) search using the terms bdnf AND sciatic AND ligation, bdnf AND 
sciatic AND constriction, bdnf AND sciatic AND transection, bdnf AND spinal AND nerve 
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AND ligation, bdnf AND spinal AND nerve AND constriction, bdnf AND spinal AND 
nerve AND transection was performed. Articles with a publication date up to January 1, 
2009 were included. This resulted in 11, 13, 45, 20, 14 and 48 references, respectively. 
The literature was categorized in experiments using a sciatic nerve chronic constriction 
injury, a sciatic nerve transection injury, a spinal nerve ligation model and a spinal 
nerve transection (SNT) model. The results and figures pertaining to the spinal nerve 
ligation and spinal nerve transection models have been published online as results S1 
and figure S1. 
2.3 Results 
2.3.1 BDNF expression in the sciatic nerve chronic constriction injury model 
Following a loose chronic constriction injury of the sciatic nerve, Ha [18] found an 
increased BDNF expression in small, medium and large neurons in the L4 and L5 DRG 
and in axonal fibers in the medial superficial and deeper laminae of the ipsilateral L4/5 
dorsal horn (DH) to where these neurons project. Also using a sciatic CCI model, Obata 
[19] employed activating transcription factor 3 (ATF3) expression as a neuronal injury 
marker. Although the same procedure was performed in all rats, the extent of damage 
as evidenced by the number of ATF3-labeled neurons differed significantly. Rats were 
divided into 3 groups according to the percentage of ATF3-immunoreactive (IR) neu-
rons: group 1 (<12.5%), group 2 (12.5–25%), and group 3 (>25%). The investigators 
found that only rats with substantial nerve damage (groups 2 and 3) showed thermal 
hyperalgesia, whereas only the rats in group 2 developed tactile allodynia. In groups 1 
and 2, BDNF-IR neurons were primarily of small or medium diameter whereas in these 
groups the injured neurons were mainly of medium or large diameter. In group 2, 
there was no co-localisation for ATF3 and BDNF in neurons indicating that the in-
creased BDNF expression occurred mainly in non-injured neurons. In group 3 small, 
medium- and large-sized neurons were labeled for ATF3-IR and small, medium and 
large neurons were labeled for BDNF-IR, but no co-localisation experiments were made 
in this group. The pattern of BDNF labelling in the latter group bears a resemblance to 
the results of Ha [18]. Elucidation of the cause of this differential expression of BDNF is 
provided by the pathophysiology of CCI. With loose CCI of the sciatic nerve, at the time 
of tying, the ligatures just barely reduce the nerve diameter. Over time, the ligatures 
evoke intraneural edema, resulting in constriction of the nerve. Electron microscopic 
studies of the sciatic nerve 10 to 28 days after surgery revealed destruction of most 
Aβ- and Aδ-fibers distal to the CCI. In contrast, damage to C-fibers was variable, rang-
ing between 30 and 80% [20]. Physiological studies also demonstrated that 90% of Aβ- 
and Aδ-fibers and 30% of C-fibers do not conduct through the CCI 3 days after surgery 
[21]. Thus in a CCI model C-fibers are relatively spared compared to the larger Aβ and 
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Aδ fibers. NGF is produced abundantly around degenerating Aβ and Aδ fibers by 
Schwann cells and macrophages [22-24]. This NGF is retrogradely transported by intact 
C-fibers to the dorsal root ganglion (DRG), leading to an increased production of BDNF 
in small to medium neurons. Corroborating the hypothesis of changed target derived 
NGF as cause of altered BDNF expression, Obata [25] administered recombinant NGF 
intrathecally (i.t.) in Sprague-Dawley rats and found an increased BDNF expression in 
small and medium DRG neurons. 
 Intracellular signal transduction pathways involved in the pathophysiological 
mechanisms of neuropathic pain after sciatic nerve CCI also vary according to the 
damage inflicted to the DRG neurons [25]. The mitogen-activated protein kinase 
(MAPK) pathway involvement in neurotrophin dependent survival and differentiation 
of developing peripheral neurons has been clearly established [26-29]. The MAPK 
family includes the extracellular signal-regulated protein kinases (ERK), p38 MAPK, c-
Jun N-terminal kinase (JNK) and ERK5. ERK is involved in cellular growth and differenti-
ation, whereas p38 and JNK participate in injury responses and cell death. After CCI 
there is a phosphorylation of ERK predominantly in injured ATF3-positive medium and 
large DRG neurons and in satellite glial cells. CCI also increased the expression of NPY 
in these neurons. Treatment with the MAPK kinase 1⁄2 inhibitor, U0126, suppressed 
CCI-induced mechanical allodynia and partially reversed the increase in NPY expres-
sion. In contrast, CCI induced the activation of p38, mainly in uninjured ATF3-
immunonegative unmyelinated small to medium DRG neurons and in satellite glial 
cells. In intact DRG neurons, the p38 inhibitor, SB203580, reversed CCI-induced me-
chanical allodynia and heat hyperalgesia, and also blocked the increase in BDNF ex-
pression. I.t. administration of NGF increased BDNF expression in small-to-medium-
sized neurons, which could be reversed by SB203580, whereas anti-NGF increased NPY 
in medium-sized and large-sized neurons, which could be partially blocked by U0126. 
 CCI not only induces changes in BDNF expression in the DRG but also in the dorsal 
horn (DH). Sprague-Dawley rats exhibiting thermal hyperalgesia after sciatic CCI exhib-
ited a significant increase in the concentration of BDNF in their lumbar spinal DH [30]. 
Following the disappearance of thermal hyperalgesia 28 days after loose ligation of the 
sciatic nerve, there was no difference in DH BDNF level between control rats and 
animals with sciatic ligations, suggesting a close association in the timeline of the 
development and disappearance of behavioural signs of neuropathic pain with chang-
es in BDNF level in the lumbar spinal DH. Furthermore, Yajima [31, 32] established an 
increase in BDNF and its full-length TrkB receptor in the ipsilateral superficial laminae 
of the DH after sciatic CCI. I.t. application of BDNF-antibody or TrkB/Fc prevented the 
development of thermal hyperalgesia and abolished the increase in full-length TrkB 
receptor in the dorsal horn. TrkB/Fc contains the extracellular ligand-binding domain 
of a TrkB receptor followed by the hinge and Fc region of human IgG1 and acts as TrkB 
receptor body to sequester endogenous BDNF and neurotrophin-4/5. The induced 
thermal hyperalgesia was also reversed by i.t. administration of antibody raised against 
C H A P T E R  2  
 30 
the full-length TrkB receptor, K252a (an inhibitor of the tyrosine kinase activity for the 
neurotrophin receptor) or the selective PKC inhibitor Ro-32-0432, but i.t. injection of 
an antibody to the truncated TrkB receptor or to NT4 failed to relieve thermal hyperal-
gesia. Additionally, a single i.t. injection of BDNF produced a marked and long lasting 
thermal hyperalgesia and tactile allodynia in normal mice after the injection. This 
effect was abolished by i.t. pre-treatment with K-252a or the selective PKC inhibitor 
Ro-32-0432. Balasubramanyan [33] used spinal cord slices of rats that underwent a 
sciatic CCI and Lu [34] used defined-medium organotypic cultures consisting of embry-
onic Sprague-Dawley spinal cord and DRG neurons treated with BDNF 200 ng/ml. Both 
investigators found identical results with patch clamp techniques, namely increases in 
excitatory synaptic drive to putative excitatory ‘delay’ firing neurons in the substantia 
gelatinosa but decreased synaptic drive to putative inhibitory ‘tonic’ firing neurons. 
Effects of BDNF on putative excitatory ‘delay’ neurons were exclusively presynaptic, 
whereas both pre- and post-components were involved in BDNF's action on putative 
inhibitory ‘tonic’ neurons. These BDNF-induced changes in synaptic drive contributed 
to an overall increase in DH excitability thus promoting a state of central hypersensitiv-
ity as seen in the sciatic CCI model. The mechanism by which BDNF enhances synaptic 
transmission could be phosphorylation of CREB Ser133 by acting on its high-affinity TrkB 
receptor, thus promoting a cascade of events leading to synapse specific efficacy [35]. 
 An increasing number of studies indicate that pain is not solely mediated by 
neurons but that microglia and astrocytes have an active role in the initiation and 
maintenance of neuropathic pain. Zhang and De Koninck [36] found that spinal micro-
glia were activated after sciatic CCI by monocyte chemoattractant protein-1 produced 
by damaged DRG neurons which is subsequently transported to the afferent nerve 
terminals in the DH. An intact dorsal root seems essential to convey DRG mediated 
signals for activation of spinal microglia [37]. Another way in which microglia may 
contribute to neuropathic pain is through the activation of their P2X4 receptor by ATP 
[38]. This leads to an influx of extracellular calcium and subsequent activation of p38 
MAPK resulting in an increased synthesis and release of BDNF through soluble N-
etylmaleimide-sensitive factor attachment protein receptor dependent exocytosis [39]. 
Furthermore, the release of BDNF is biphasic with an initial release of a pre-existing 
pool of BDNF followed by an increase in de novo synthesis of BDNF. Coull [40, 41] 
discovered that BDNF released by ATP-stimulated microglia causes a depolarizing shift 
in the anion reversal potential of lamina I neurons by ways of a reduction in the ex-
pression of the potassium-chloride exporter KCC2. Normally inhibitory anionic synaptic 
currents activated by GABA are thus rendered excitatory leading to a disinhibition of 
the DH and neuropathic pain. In a more recent study Lu [42] corroborated the findings 
of their earlier study and moreover identified the inhibitory neurons as GABAergic and 
the excitatory neurons as non-GABAergic using glutamic acid decarboxylase. Even 
more important in this study was the fact that addition of activated microglia to 
organotypic cultures increased the overall excitability of the DH as was seen by adding 
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BDNF. The effect of activated microglia was abrogated by the recombinant protein 
TrkB-d5, which binds and inactivates all neurotrophins that interact with TrkB recep-
tors, confirming the earlier findings that activated microglia may be an important 
source of BDNF in neuropathic pain syndromes. Another possible mechanism by which 
BDNF induces central hypersensitivity is by enhancing NMDA receptor-mediated 
responses in the DH [43]: the ventral root potential is routinely used as an indirect but 
accurate measure of spinal excitability. NMDA-evoked ventral root depolarization 
amplitudes increased significantly after BDNF superinfusion in isolated hemisected 
spinal cords. 
 Finally, gonadal hormones appear to influence BDNF expression and pain behav-
ior. Zhao [44, 45] studied the effect of estrogen on neuropathic pain using a sciatic CCI 
model in female Sprague–Dawley rats. Animals with high estrogen levels responded 
significantly faster to thermal nociceptive stimuli then ovariectomized rats. The former 
rats also had higher BDNF mRNA in the ipsilateral DRG’s and a higher BDNF protein 
level in the spinal cord, suggesting the presence of an estrogen-responsive element in 
the BDNF gene. The summarized data are found in Fig. 1. 
 
 
Figure 1. BDNF expression in the sciatic nerve chronic constriction injury and sciatic nerve transection
models (BDNF: brain-derived neurotrophic factor, NGF: nerve growth factor, DRG: dorsal root ganglion,
NMDA: N-methyl-D-aspartate, KCC2: potassium-chloride co-transporter 2, GABA: γ-aminobutyric acid, NGF: 
nerve growth factor, CCI: chronic constriction injury, p38: p38 mitogen-activated protein kinase, ERK: 
extracellular signal-regulated protein kinases, NPY: neuropeptide Y, MCP-1: monocyte chemoattractant 
protein-1, ATP: adenosine triphosphate, P2X4: purinoreceptor P2X4, : increase, : decrease). 
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2.3.2 BDNF expression in the sciatic nerve transection model 
Meyer [46] and Funakoshi [47] found a continuous slow increase in BDNF mRNA in the 
sciatic nerve after transection, starting 3 days after the lesion and reaching maximal 
levels 3-4 weeks later. The final levels were 10 times higher than those of NGF mRNA. 
The increase in BDNF was independent of activated macrophages and IL-1β and was 
probably generated by Schwann cells, findings corroborated by Friedman using myelin-
deficient Trembler mice [48]. Tonra [49] also demonstrated an increased transport to 
the injury site of BDNF after a sciatic crush lesion. The source of this BDNF seemed to 
be sensory neurons in the DRG. So, in addition to an increased BDNF production at the 
injury site by Schwann cells, an additional amount of BDNF may be supplied through 
anterograde transport of BDNF produced by DRG neurons. 
 Cho [50] and Zhou [51] were the first to demonstrate a switch in phenotype in 
primary sensory neurons after sciatic nerve transection in Sprague-Dawley rats. Nor-
mally expressed in small to medium DRG neurons, BDNF was now expressed in larger 
sensory neurons (with a surface of >600 µm2) in the ipsilateral L4 and L5 DRG. There 
was no significant change in the contralateral DRG. In the DH, BDNF-IR, which is nor-
mally localized in large electron-dense core vesicles in neurons of the superficial layers, 
now increased in laminae III and IV and diminished in laminae I and II. Michael [52] and 
Kashiba and Senba [53] confirmed these findings in a sciatic nerve transection model in 
male Wistar rats. They found a significant increase in BDNF expression in ipsilateral 
TrkB- and TrkC-containing medium-to-large DRG neurons. BDNF-IR was extensively co-
expressed with galanin and NPY in large DRG neurons. BDNF expression in the DH also 
shifted towards the deeper lamina IV as was confirmed by Walker [54]. Since BDNF 
expression in small DRG neurons is NGF-dependent, deprivation of target-derived NGF 
serves as a basis for downregulation of BDNF expression in these neurons and their 
endings in laminae I and II of the DH. Until recently, large DRG neurons were believed 
to be independent of NGF due to a lack of TrkA receptors, but Karchewski [55] showed 
that 19% of DRG neurons express both TrkA and TrkC receptors and that the expres-
sion of two or three Trk receptor mRNAs by the same neuron occurs almost exclusively 
in medium-sized to large neurons. Therefore, in normal circumstances, NGF may 
inhibit BDNF expression in large DRG neurons. With sciatic transection the negative 
feedback loop is interrupted and BDNF expression stimulated. Corroborating this 
hypothesis was the finding by Obata [56] that i.t. administered anti-NGF induces an 
increase in BDNF and NPY expression in medium to large DRG neurons. Another 
possible explanation is an increase in intracellular calcium concentration, either by 
direct influx or through the NMDA receptor, which would upregulate BDNF through a 
CREB transcription factor-dependent mechanism. Finally, a negative feedback by 
target-derived NT3, the survival factor for large DRG neurons, could be a possibility. In 
view of the fact that not only target-derived NGF but also NT3 is deficient after nerve 
lesion, inhibition in large neurons disappears and BDNF expression is upregulated. 
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Supporting this evidence is a study by Ohara [57] where sciatic nerve transection 
induced a rise in NPY-IR in medium and large DRG neurons and in laminae III and IV of 
the DH, which is abolished by exogenous administered NT3. 
 Obata [56] looked into the intracellular signal transduction pathways involved in 
regulating the gene expression of BDNF in primary afferent neurons after sciatic nerve 
transection. Axotomy induced the activation of ERK and upregulation of BDNF mainly 
in medium- and large-sized DRG neurons and in satellite glial cells as did the applica-
tion of anti-NGF. 
 Marcol [58] provided evidence for a relationship between neuropathic pain and 
BDNF at the site of nerve injury by supplying the proximal nerve stump of transected 
sciatic nerves with connective tissue chambers filled with fibrin only, with fibrin and 
BDNF, or with fibrin and anti-BDNF. Rats usually began to self-mutilate the denervated 
limbs within the first week following nerve transection. Local application of BDNF not 
only brought forward the onset of autotomy but also increased the incidence and 
severity of autotomy behaviour. In contrast, local inhibition by anti-BDNF antibody 
decreased neuroma formation and the incidence and severity of autotomy, whereas 
survival and regeneration of DRG cells were not affected. Several explanations are 
possible to elucidate these findings. First, peripheral BDNF stimulates neuroma for-
mation [58]. Since neuromata are known to cause neuropathic pain, local inhibition of 
BDNF will prevent this effect. Secondly, sequestration of locally produced BDNF by 
means of BDNF-antiserum averts proximal transportation, thereby inhibiting nocicep-
tive pathways in the DRG or DH. Thirdly, anti-BDNF is transported proximally and 
inhibits BDNF at the DRG or DH. 
 In a brachial plexus avulsion model, Quintao [59] was able to reproduce the 
results by Marcol [58], by local application of anti-GDNF, anti-BDNF, anti-NT3 and anti-
NGF antibodies at the time of surgery. Mechanical hypernociception was prevented, 
with highest potency of anti-GDNF followed by anti-BDNF, anti-NT3 and anti-NGF 
antibody. 
 Neuropathic pain can be relieved not only by inhibiting BDNF at the site of sciatic 
nerve transection but also by inhibiting BDNF at the level of the DRG or DH. Inhibiting 
the intracellular transduction pathway leading to an increased BDNF production in 
large DRG neurons by administering U0126 suppressed the axotomy-induced autoto-
my behaviour [56]. Ultimately, Park [60] noticed a reduction in expression of voltage-
gated potassium channels Kv 1.2, 1.4 and 4.2 in DRG neurons of adult male Sprague-
Dawley rats after sciatic nerve transection. In in vitro cultured DRG neurons application 
of BDNF and NT3 but not of NGF produced similar effects on Kv 1.2 and 1.4. Kv 4.2 
expression that could not be altered by any neurotrophin. The summarized data are 
found in Figure 1. 
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2.4 Discussion 
In the sciatic CCI model small C-fibers are relatively spared compared to larger Aβ and 
Aδ fibers. Wallerian degeneration and inflammation induce NGF production in 
Schwann cells and macrophages and this NGF is retrogradely transported by intact C-
fibers to small and medium DRG neurons. In these neurons NGF binds its TrkA recep-
tor, increasing BDNF production by a p38 MAPK-dependent intracellular transduction 
pathway. BDNF is transported to the superficial laminae of the DH where in turn it 
binds its TrkB receptor inducing thermal hyperalgesia and mechanical allodynia 
through secondary pathways involving PKC. Moreover, primary sensory neurons 
release BDNF in an activity-dependent manner indicating that BDNF can encode 
temporal features of presynaptic neuronal activity. High frequency bursts are more 
effective in releasing BDNF than continuous depolarization or tonic electrical stimula-
tion [61]. The role of spinal microglia in the development and maintenance of neuro-
pathic pain becomes evermore important. After sciatic CCI spinal microglia is activated 
by monocyte chemoattractant protein-1 and ATP. The latter induces an influx of 
extracellular calcium by binding its P2X4 receptor subsequently increasing release and 
de novo synthesis of BDNF in a p38 MAPK-dependent manner. This leads to disinhibi-
tion of the DH that is the result of increased excitatory synaptic drive to putative 
excitatory ‘delay’ firing neurons in the substantia gelatinosa and decreased synaptic 
drive to putative inhibitory ‘tonic’ firing neurons. The depolarizing shift in the anion 
reversal potential of lamina I neurons that lays at the basis of this phenomenon is the 
result of a reduction in the expression of the potassium-chloride exporter KCC2. 
Sensitization of the NMDA receptor additionally contributes to a state of central 
hypersensitivity. In contrast, there is an upregulation of NPY in damaged large neurons 
in the CCI model also causing mechanical allodynia. ERK seems to be a main player in 
this event. A noteworthy observation in the CCI model made by Obata [19] is that the 
extent of the injury evoked by loose ligatures varies significantly even if performed by 
one investigator. 
 Sciatic nerve transection increases BDNF at the site of injury. The source of this 
BDNF seems to be an increased BDNF production by Schwann cells as well as an 
intensified anterograde transport of BDNF produced in the sensory neurons of the 
DRG. In contrast to the sciatic CCI model, in the sciatic nerve transection model BDNF 
is upregulated in medium to large DRG neurons and in the deeper laminae III and IV of 
the DH and BDNF expression decreases in small DRG neurons and their projections in 
the superficial laminae I and II of the DH. Again ERK seems to be the important intra-
cellular transduction pathway in large neurons. There is extensive co-localisation of 
BDNF and NPY in the large neurons. The diminished BDNF expression in small neurons 
is caused by diminution in target-derived NGF. Several mechanisms have been postu-
lated for the increase in BDNF expression in large neurons, ranging from depletion in 
target-derived NGF and/or NT3 to an increase in intracellular calcium concentration 
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either by direct influx or through the NMDA receptor. Although, it seems unlikely that 
in the sciatic nerve transection model such an increase in intracellular calcium would 
occur through calcium channels since Baccei and Kocsis [62] demonstrated a reduction 
in high-voltage-activated calcium channel currents mainly through a reduction in N-
type calcium current. NMDA receptors are present in peptidergic and non-peptidergic 
primary afferent neurons in the DRG [63]. Nonetheless proof is still needed that 
extracellular glutamate is present to activate these NMDA-receptors. A causal relation-
ship between increased BDNF expression in sciatic transection models and neuropathic 
pain is established by experiments in which application of anti-BDNF at the site of 
nerve transection or i.t., or administration of inhibitors of the intracellular transduction 
pathway diminish mechanical allodynia. 
 The spinal nerve ligation model increases BDNF expression in medium to large 
neurons of the DRG, whereas in uninjured DRG the increase was mainly seen in small 
to medium neurons and to a lesser extent in large neurons. After injury there was an 
increase in phosphorylated ERK in large neurons whereas p38 and JNK were activated 
in small- to medium-sized neurons. In the uninjured level an increase in phosphory-
lated p38 was noticed in small to medium neurons. An amplified NGF production in the 
sciatic nerve or L5 spinal nerve seems to be retrogradely transported to the L4 DRG 
inducing an increase in BDNF production in small- to medium-sized DRG neurons. The 
mechanism of increased BDNF expression in large neurons in the uninjured DRG needs 
to be elucidated but possibly large neurons co-expressing TrkA and TrkC receptors may 
play a key role. A remarkable finding in SNL experiments is that thermal hyperalgesia 
seems to be mediated by uninjured DRG while mechanical allodynia is mediated by 
injured DRG. 
 Spinal nerve transection increases BDNF expression in medium to large DRG 
neurons as does dorsal or combined dorsal/ventral rhizotomy. Ventral rhizotomy alone 
results in enhanced BDNF expression in small to medium DRG neurons whereas only 
lesions distal to the DRG (SNT) lead to an increased BDNF expression in the L4 DRG. 
Besides neuropathic pain, SNT also gives rise to sympathic basket formation and 
sprouting around large DRG neurons. Peripherally applied antisera to NGF, NT3 and 
BDNF attenuate allodynia and sympathic sprouting at different allodynia stages, with 
BDNF antiserum acting during early and advanced stages but NGF and NT3 antisera 
acting only during the advanced stage. Blocking BDNF reduces allodynia and sympathic 
sprouting the longest although the strongest suppression is achieved by antisera to 
NT3. The findings of the literature review are recapitulated in Table 1. 
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Table 1. Summary of the literature findings regarding BDNF expression in different animal models of 
neuropathic pain (CCI: chronic constriction injury, SNL: spinal nerve ligation, SNT: spinal nerve transection, 
ERK: extracellular signal-regulated protein kinases, p38: p38 mitogen-activated protein kinase, DRG: dorsal 
root ganglion, DH: dorsal horn, BDNF: brain-derived neurotrophic factor, NGF: nerve growth factor, NT3: 
neurotrophin 3, Ca++: calcium ion) 
Type of nerve 
lesion 
Type of neurons 
injured 
Increased BDNF expression
DRG neurons 
(intracellular 
transduction pathway) 
DH laminae Mechanism 
Sciatic Nerve CCI medium,large small, medium (p38) I, II Increased NGF production 
by degenerating Aβ and 
Aδ fibers, retrogradely 
transported by intact C 
fibers 
Sciatic Nerve 
Transection 
small, medium, 
large 
medium, large (ERK) III, IV Deprivation of NGF in C 
fibers. Depletion of NGF 
or NT3 or increased 
intracellular Ca++ in Aδ, Aβ 
fibers?
L5 SNL medium, large  medium, large in the L5 
DRG (ERK) small, medium 
in the L4 DRG (p38) 
I, II, III, IV Increased NGF production 
at the ligation site, 
transported to the L4 DRG 
L5 SNT small, medium, 
large 
medium, large in the L5 
DRG 
Undetermined Deprivation of NGF in C 
fibers. Depletion of NGF 
or NT3 or increased 
intracellular Ca++ in Aδ, Aβ 
fibers?
 
Although a body of evidence exists for a pronociceptive function of BDNF, contradicto-
ry data are found in the literature claiming an antinociceptive effect. In a unilateral CCI 
of the rat sciatic nerve Cejas [64] succeeded in reversing cold and tactile allodynia and 
hyperalgesia by lumbar subarachnoid transplantation of BDNF secreting neurons. 
There was no change in sensory behaviours in a control group. The antinociceptive 
effects of intrathecal BDNF are thought to arise from BDNF’s ability to increase the 
synthesis and release of serotonin in descending raphe serotonergic/peptidergic 
neurons or by rescuing central GABA neurons and stimulating GABA release, both 
providing inhibitory modulation of the DH. Furthermore, using the unilateral sciatic CCI 
model in female Wistar Furth rats, Eaton [65] succeeded in reversing allodynia and 
hyperalgesia by adeno-associated viral vector mediated overexpression of BDNF in the 
spinal cord. They injected the vector into the dorsal spinal gray matter of the first 
lumbar segment. In situ hybridization demonstrated that both dorsal and ventral 
lumbar spinal neurons contained an intense signal for BDNF mRNA, one week after 
vector injection. Lever [66] investigated the release of BDNF and GABA in a DH with 
dorsal roots attached preparation obtained from spinal nerve lesioned male Wistar 
rats. They demonstrated that BDNF facilitates the release of GABA through activation 
of TrkB receptors in the dorsal horn. GABA activates the GABAA receptor found on 
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large myelinated fibers to mediate GABA-induced depolarization of primary afferent 
fibers and GABAB receptor in unmyelinated fibers to mediate GABA-induced inhibition 
of neurotransmitter release. Contrary to other reports, these investigators found that 
a single i.t. injection of BDNF relieves thermal hyperalgesia after SNL. This effect was 
blocked by the GABA receptor antagonist CGP 55445, suggesting this effect was medi-
ated by the release of endogenous GABA from interneurons. 
 One possible explanation for the conflicting evidence may be interspecies differ-
ences in expression of neuropathic pain and BDNF [67]. Even though the levels of 
expression of BDNF in naive F344, Lewis and Sprague-Dawley rats are very similar, 
after sciatic CCI, only F344 rats completely recovered from mechanical allodynia, after 
28 days. The increase in BDNF mRNA level after CCI was only significant in injured DRG 
of F344 rats. Moreover, differences in acute inflammatory and neuropathic pain in 
Lewis and Fischer rats seem to be correlated with the lower levels of circulating corti-
costerone due to a hypofunctional hypothalamo-hypophyseal adrenal axis [68]. Carr 
[69] found that the behavioral response of Sprague–Dawley rats to nerve injury is 
more intense than that of Wistar rats. Also intraspecies disparity between male and 
female animals in the expression of BDNF and neuropathic pain may cause incon-
sistency. In addition, differences in the time between the initial nerve perturbation and 
the examination of DRG cells in different studies presents yet another source of dis-
crepancy because the spontaneous activity induced by nerve injury peaks at 13 days 
and returns to a lower level after 30 days [70]. Also the loss of thermal hyperalgesia is 
a normal feature of the loose ligation, although the time at which hyperalgesia disap-
pears, varies [6]. Variations in seemingly similar techniques to induce neuropathic pain 
may cause different degrees of neuronal damage, as has been demonstrated by ATF3 
labeling in a sciatic CCI by Obata [19]. There is also the possibility that the distance 
between the site of injury and the DRG may affect the intensity of changes seen in cell 
bodies [71]. In addition, differences in the age of animals used in different studies may 
have been a factor of variability [55, 72]. Peripheral axotomy promotes much more cell 
death in the DRG of young animals than in older animals [73]. Finally, Miki [74] demon-
strated that the dose of systemically administered BDNF influences the final outcome 
on neuropathic pain. Whereas low doses of BDNF can suppress mechanical allodynia, 
high doses have the opposite effect. 
2.5 Conclusions 
Animal models yielded large amounts of experimental data that indicate the important 
role of BDNF in neuropathic pain. Yet, these data are not always conclusive because 
the respective studies differ as to species, gender and age of animals used and because 
the cell types studied have not been exactly identified. Future studies with more strict 
experimental paradigms and protocols, may solve this problem. More insight into the 
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involvement of BDNF in neuropathic pain may emerge from detailed investigation into 
the differential translation of the multiple BDNF transcripts and their actions on extra-
cellular receptors as well as on intracellular targets [75]. Such studies may provide the 
basis for the development of BDNF-based drugs for neuropathic pain treatment. 
2.6 Abbreviations 
ATF3 activating transcription factor 3 
BDNF brain-derived neurotrophic factor 
CCI chronic constriction injury 
DH dorsal horn 
DRG dorsal root ganglion 
ERK extracellular signal-regulated protein kinases 
GABA γ-aminobutyric acid 
IR immunoreactive 
i.t. intrathecally 
JNK Jun N-terminal kinase 
KCC2 potassium-chloride co-transporter 2 
MAPK mitogen-activated protein kinase 
NGF nerve growth factor 
NPY neuropeptide Y 
NT3 neurotrophin 3 
NT4 neurotrophin 4 
NT5 neurotrophin 5 
P38 p38 mitogen-activated protein kinase 
P75NTR p75 neurotrophin receptor 
SNL spinal nerve ligation 
SNT spinal nerve transection 
Trk tropomyosin-related kinase 
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Results supplement published online 
BDNF expression in the spinal nerve ligation model 
In a spinal nerve ligation model inflammatory mediators and neurotrophins produced 
by Wallerian degeneration of the ligated L5 and L6 spinal nerve can interact with intact 
L4 fibers. Ha [1] performed a tight L5-L6 spinal nerve ligation in male Sprague-Dawley 
rats and found a decrease in BDNF expression in small DRG neurons with an increase in 
medium and large DRG neurons at the L5 and L6 level. In the ipsilateral L4 DRG small, 
medium and large DRG neurons showed an increased BDNF-IR. A considerable in-
crease in the expression of BDNF-IR axonal fibers in the medial superficial and deeper 
laminae of the ipsilateral L4/5 DH was observed. This pattern of BDNF expression 
resembles more a transection model than a CCI model if we compare it with data 
obtained from sciatic nerve models. A possible explanation may be found in the tight-
ness with which the ligatures were applied. Normally for CCI injury loose ligations are 
made hereby causing intraneural edema and constriction of the nerve over days, in 
this way sparing the smaller C-fibers and injuring only the larger Aβ and Aδ fibers. With 
tight ligatures it is likely that all fibers are injured, resembling to some extent a tran-
section model. Why small, medium and large neurons in the L4 DRG start to express 
BDNF is open to discussion. NGF produced by Wallerian degeneration of the L5 and L6 
spinal nerve could be retrogradely transported to the L4 DRG, stimulating BDNF pro-
duction in small and medium neurons, but Shen [2] demonstrated an increased NGF 
and BDNF mRNA expression in the DRG after a SNL. Identical results concerning BDNF 
expression in the uninjured L4 DRG in a L5 SNL model were obtained by Fukuoka [3]. 
The increased BDNF expression mainly took place in TrkA positive small- (<600µm2) 
and medium-sized (600-1200µm2) neurons but also in a subset of large neurons. I.t. 
administration of a BDNF antiserum attenuated thermal hyperalgesia for a few hours. 
Furthermore, NGF but not NGFmRNA content increased in L4 DRG. NGFmRNA did 
increase in the L5 DRG and in the sciatic nerve, indicating that NGF synthesized in the 
sciatic nerve or the L5 spinal nerve diffuses into the spared L4 spinal nerve. Additional-
ly, local application of a NGF antiserum to the L4 spinal nerve delayed the develop-
ment of thermal hyperalgesia but did not prevent it. Remarkably, NGF antiserum did 
not block the increased BDNF expression in the ipsilateral L4 DRG. This is in contrast 
with the experiment by Obata [4] where NGF antiserum blocked BDNF expression in 
the L4 DRG after an L5 SNL. Moreover, the molecular processes involved in the mani-
festation of neuropathic pain in an L5 SNL were investigated. In the injured L5 DRG, the 
L5 SNL induced the activation of ERK in medium to large neurons and p38 and JNK in 
small- to medium-sized DRG neurons. In contrast, in the uninjured L4 DRG, an L5 SNL 
only induced p38 activation in TrkA-expressing small- to medium-diameter C-fiber 
neurons. I.t. infusions of the MEK1/2 inhibitor U0126 and the JNK inhibitor SP600125 
reversed SNL-induced mechanical allodynia, events that could only be blocked by the 
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p38 inhibitor SB203580. An L5 dorsal rhizotomy made immediately before an L5 SNL 
prevented the development of mechanical allodynia but was not able to block SNL-
induced thermal hyperalgesia indicating that this hyperalgesia originates in the L4 
DRG. Further corroborating this evidence is the fact that an L4 dorsal rhizotomy exe-
cuted after the L5 SNL reversed not only mechanical allodynia but also thermal hyper-
algesia. Activation of p38 in the uninjured L4 DRG might therefore be involved in the 
development of heat hypersensitivity in the L5 SNL model. An L5 SNL induced an 
increase in BDNF mRNA seen mainly in small- and medium-sized p-38 positive L4 DRG 
neurons. Treatment with a p38 inhibitor and with NGF antiserum reduced SNL-induced 
upregulation of BDNF expression in the L4 DRG. These findings suggest that after L5 
SNL, NGF synthesized and released in the degenerative nerve fibers acts on nearby 
sensory fibers along the course of the nerve and induces p38 activation in the adjacent 
intact small to medium TrkA expressing L4 DRG neurons. This may lead to an increased 
expression of BDNF and thermal hyperalgesia and mechanical allodynia. 
 Ten days after an L5 and L6 SNL in male Sprague-Dawley rats, Hayashida [5] found 
an increase in BDNF content in L5 and L6 (injured) DRG’s and in the L4 (uninjured) DRG. 
No indication as to the size of the neurons concerned was made. There was a coincid-
ing increase in noradrenergic fiber density in the DH at L4, L5 and L6. Although i.t. 
infusion of anti-BDNF did not change mechanical allodynia, it did reduce noradrenergic 
axons in the spinal cord as well as the efficacy of 15 µg i.t. applied clonidine on me-
chanical allodynia, indicating a key role for BDNF in sprouting of noradrenergic fibers in 
neuropathic pain states. 
 The summarized data are found in Figure S1. 
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Figure S1. BDNF expression in the spinal nerve ligation and spinal nerve transection model (BDNF: brain-
derived neurotrophic factor, DRG: dorsal root ganglion, NGF: nerve growth factor, p38: p38 mitogen-
activated protein kinase, ERK: extracellular signal-regulated protein kinases, : increase, : decrease). 
 
BDNF expression in the spinal nerve transection model. 
Of all the neuropathic animal models, the spinal nerve transection model is the least 
researched with regard to BDNF expression. Obata [6] studied the effect of nerve 
injury site on BDNF expression and neuropathic pain behaviour 7 days after lesion. At 
the L5 level they performed either a unilateral dorsal rhizotomy, a ventral rhizotomy, a 
dorsal and ventral rhizotomy or a spinal nerve transection. All procedures induced an 
increase in BDNF mRNA and protein in the L5 DRG. In the dorsal rhizotomy, dorsal and 
ventral rhizotomy and spinal nerve transection groups the increase in BDNF-IR was 
mainly visible in medium and large neurons whereas in the ventral rhizotomy group 
increased BDNF-IR was mainly seen in small and medium neurons. Mechanical allo-
dynia and heat hypersensitivity were apparent only in the ventral rhizotomy and spinal 
nerve transection groups, underlining the need for an intact dorsal root for the trans-
portation of BDNF from the medium and large DRG neurons to the DH and the subse-
quent development of neuropathic pain behaviour. Furthermore, an increase in L4 
BDNF-IR was noted only in the L5 spinal nerve transection group, indicating that only a 
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lesion distal to the L5 DRG can change the phenotype of the intact L4 DRG. Since 
degenerating fibers initiate a cascade of cellular and molecular events that ultimately 
lead to an accumulation of chemokines, cytokines and growth factors, the authors 
speculated that the products of Wallerian degeneration of L5 nerve fibers induced 
phenotypic changes in the L4 DRG. However, after dorsal and ventral rhizotomy the 
same products of Wallerian degeneration are produced and should also induce pheno-
typic changes in the L4 DRG, making this hypothesis incorrect or at least incomplete. In 
an L5 spinal nerve transection model, Zhou [7] administered antibodies to NGF, BDNF 
and NT3 in the L5 DRG. Foot withdrawal to Von Frey filaments was reduced compared 
to controls in all antibody groups. Antibodies to NGF acted during the early phase 
whereas anti-BDNF and anti-NT3 antibodies were effective during the later phase. No 
synergistic effect was observed by combining antibodies. The delivery of neurotrophins 
in normal DRG leads to mechanical allodynia, which occurred fastest when NGF was 
applied (4 hours) followed by BDNF (3 days). NT3 had only a short-lived effect of 1 day 
whilst the effect of NGF and BDNF lasted for the whole duration of the experiment (7 
days). 
 In peripheral nerve injury, noradrenergic perivascular axons sprout into the DRG 
to form baskets around large diameter neurons and are implicated in neuropathic pain 
after nerve injury [8]. These sprouting fibers are associated with reactive satellite cells 
that produce NGF, BDNF and NT3. Expression of the p75 nerve growth factor receptor 
in glia and neurons is required for basket formation but not for the sprouting of sym-
pathetic axons in DRG [9]. Deng [10] administered antisera specific to NGF, NT3, and 
BDNF intraperitoneally twice a week for 2 weeks in male Sprague–Dawley rats that 
underwent transection of the L5 spinal nerve. They found reduced sympathetic sprout-
ing and reduced formation of baskets. Foot withdrawal responses to von Frey hair 
stimuli were attenuated. The effect of anti-BDNF occurred earlier and lasted longer 
than that of NGF and NT3 antisera. Anti-NT3 is most potent in reducing the sprouting 
of noradrenergic fibers, followed by NGF and BDNF. Sympathetic sprouting was re-
duced by about 60%, a similar extent as that blocked by anti-neurotrophins directly 
delivered to DRG. The summarized data are found in Figure S1. 
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Abstract 
Background and Objectives 
In animal models of neuropathic pain (NP), promising results have been reported with 
the administration of minocycline, possibly through inhibition of spinal brain-derived 
neurotrophic factor (BDNF) expression. No data are available on the effect of amitrip-
tyline and gabapentin on spinal BDNF expression. If the mechanism of action of the 
latter drugs does not involve BDNF inhibition, further clinical research into BDNF is 
warranted. 
Methods 
In this placebo-controlled study, we investigated the effects of amitriptyline (5mg/kg), 
gabapentin (50mg/kg) and minocycline (25mg/kg) twice a day on NP behavior in a 
sciatic chronic constriction injury (CCI) rat model. Drug treatment started 7 days after 
CCI and lasted 14 days. At postoperative day 21, spinal BDNF expression in laminae I 
and II was quantified using immunocytochemistry. 
Results 
Sciatic CCI resulted in NP behavior throughout the duration of the experiment in the 
placebo group. When administered for 2 weeks, minocycline (P≤0.001) and amitripty-
line (P≤0.05), but not gabapentin, reduced thermal hyperalgesia. None of these drugs 
reduced mechanical allodynia. As opposed to amitriptyline and gabapentin, 2 weeks 
treatment with minocycline reduced BDNF-immunoreactivity (P≤0.05) in the ipsilateral 
dorsal horn. 
Conclusions 
Minocycline and amitriptyline both reduce NP behavior in a sciatic CCI injury rat 
model, but only minocycline reduces spinal BDNF indicating different modes of action 
of these 2 drugs. The observed actions of minocycline closely fit the clinical needs for 
the treatment of NP. 
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3.1 Introduction 
Neuropathic pain (NP) arises as a direct consequence of a lesion or disease affecting 
the somatosensory system. First-line pharmacological treatment is based either on 
increasing central nervous system serotonin and norepinephrine levels by tricyclic 
antidepressants and selective serotonin and norepinephrine reuptake inhibitors or on 
decreasing glutamate and substance P release by blocking the α2-δ subunit of voltage-
gated calcium channels with anticonvulsant drugs. However, despite these therapeutic 
modalities, NP often persists [1]. Moreover, adverse effects of these drugs often limit 
or prohibit their use. Consequently, there is an urgent need for novel targets and drugs 
to improve current NP treatment. 
 Neurotrophins can be such targets. Their superfamily consists of nerve growth 
factor, brain-derived neurotrophic factor (BDNF) and neurotrophins 3 and 4/5. Each 
family member exerts its function through its own high affinity tropomyosin-related 
receptor kinase (Trk) and a shared low affinity p75 neurotrophin receptor. During the 
past decade, BDNF was studied extensively in various animal models for NP and 
emerged as a modulator of central and peripheral nociceptive responses. Enhanced 
BDNF expression by neurons and microglia in the spinal sensory matrix favors nocicep-
tion through suppression of inhibitory mechanisms within the dorsal horn and en-
hancement of excitatory synaptic output [2]. Moreover, there is a close temporal 
relationship between the appearance and disappearance of thermal hyperalgesia and 
spinal BDNF concentration [3]. 
 Amitriptyline and gabapentin are both first-line drugs used in the treatment of NP 
[4]. In order for BDNF to be a useful new target for the treatment of NP we must first 
ascertain that these existing drugs have no effect on BDNF expression. Should amitrip-
tyline and gabapentin already significantly decrease BDNF expression, then the clinical 
usefulness of BDNF as a new target in the treatment of NP would be questionable, and 
research into new compounds to inhibit BDNF expression would seem pointless. On 
the other hand, if amitriptyline and gabapentin do not affect BDNF expression, a 
combination of drugs with different modes of action could prove helpful in the treat-
ment of NP. However, to date their effect on spinal BDNF expression has not been 
studied. Minocycline, a second-generation tetracycline, improves several neurodegen-
erative conditions and decreases NP behavior in various animal models [5, 6], possibly 
via a BDNF-dependent mechanism, yet minocycline has not found its way into clinical 
practice for pain relief. 
 The first aim of this study was to examine the effect of amitriptyline, gabapentin 
and minocycline on spinal BDNF expression and NP behavior using the well-established 
chronic sciatic nerve constriction injury (CCI) rat model for NP and quantitative im-
munocytochemistry in the dorsal horn. The second aim was to mimic the clinical 
situation by commencing drug therapy 7 days after CCI, instead of preemptively, and 
by administering these drugs for 2 weeks. Most animal studies investigating the effects 
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of amitriptyline, gabapentin and minocycline on NP involve preemptive study designs, 
with the start of drug therapy before induction of NP and the duration of therapy 
limited to 7 days maximum [7-9].However, this is not a fair reflection of the clinical 
situation as NP is a chronic condition and most patients present themselves well after 
NP has emerged. 
3.2 Methods 
3.2.1 Ethical considerations 
The study was conducted in a manner that does not inflict unnecessary pain or discom-
fort upon the animal, as outlined by the US Public Health Service Policy on Humane 
Care and Use of Laboratory Animals and the Guide for the Care and Use of Laboratory 
Animals (1996), prepared by the National Academy of Sciences’ Institute for Laborato-
ry Animal Research. All handlings were approved by the animal ethics committee of 
the Radboud University Nijmegen. 
3.2.2 Animal care 
Forty-six male Sprague-Dawley rats (Charles River Laboratories, Sulzfeld, Germany), 
weighing 340±3 g, were randomly allocated to five groups: ‘minocycline’ (n=9), ‘ami-
triptyline’ (n=8), ‘gabapentin’ (n=9), ’control’ (n=8) and ‘sham’ (n=6). Animals were 
pair-housed in plastic cages (Makrolon type III; Tecniplast, Buguggiate, Italy) for 7 days 
to acclimatize and, upon CCI- or sham-surgery, during the next 3 weeks of experimen-
tation, in a temperature- and humidity-controlled environment, on a 12/12 h light-dark 
cycle (lights on: 6:30 AM, light intensity: 200 lux), with ad libitum access to tap water 
and soy-free rodent chow. 
3.2.3 CCI-surgery 
Sciatic CCI was performed as described by Bennett and Xie [10]. In short, on experi-
ment day 0, all rats were anesthetized with isoflurane (induction 5%, maintenance 
2.5%)/nitrous oxide (65-67.5%) and the left sciatic nerve was exposed at the mid-thigh 
level proximal to the trifurcation by blunt dissection of the biceps femoris muscle. 
Next, 4 chromic catgut 5-0 ligatures (Catgut, Markneukirchen, Germany) were loosely 
applied, 1 mm apart, around the left sciatic nerve. Finally, the overlying muscle was 
sutured with Vicryl 5-0 (Johnson & Johnson, St. Stevens-Woluwe, Belgium) and the skin 
closed with autoclips (7.5 x 1.75 mm; Rudolf Medizintechnik, Fridingen, Germany). 
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Sham-operated animals underwent the same surgery but without applying nerve 
ligation. 
3.2.4 Drug treatment 
All drugs were dissolved in 0.9% NaCl. CCI rats received either 25 mg/kg body weight 
minocycline orally, 5 mg/kg amitriptyline subcutaneously (SC), 50 mg/kg gabapentin SC 
or 5 ml 0.9% NaCl/kg SC (controls) twice a day, at 7 AM and 7 PM, from day 7 till day 
21. Shams received 5ml 0.9% (wt/vol) NaCl/kg SC. Drug doses were chosen according 
to the lowest concentrations previously reported to have significant effects on NP 
behavior [11-13]. 
3.2.5 Behavioral tests 
On the day before surgery (BL; pre-surgery baseline) and on days 7, 14 and 21, 3 
behavioral tests were carried out. First, rats were tested for cold hyperalgesia on a cold 
plate apparatus (Ugo Basile, Comerio, Italy) consisting of an acrylic cylinder (diameter 
19 cm, height 31 cm) fixed to a stainless steel plate with a constant temperature of 
4°C. The numbers of left and right hind paw lifts were counted during a 5 minute 
period. Secondly, mechanical hyperalgesia was assessed with the Von Frey test [14], 
placing a rat on the mesh-wired floor of a plastic box (20 x 16 x 14 cm), for 30 minutes. 
Force-calibrated Von Frey monofilaments (Somedic AS, Stockholm, Sweden) were 
applied perpendicularly to the plantar surface of the hind paw. Brisk withdrawal or 
paw flinching were considered as positive responses. In the absence of a response, a 
filament of next greater force was applied. Each filament was tested 5 times. The 
filament that elicited 4 positive responses defined the threshold for mechanical allo-
dynia. Third, heat hyperalgesia was tested with the plantar test as described by Har-
greaves et al. [15]. After habituating rats in the mesh-wire box for 15 minutes, a heat 
stimulus was applied to the left or right hind paw, and the time till paw lifting was 
measured. Cutoff time was 20 seconds to prevent tissue damage. All tests were per-
formed during the light period. 
3.2.6 Immunocytochemistry 
All animals were killed on day 22 for quantitative immunocytochemistry. They were 
perfused transcardially under deep isoflurane anesthesia, with 100 ml 0.1 M sodium 
phosphate-buffered saline (PBS; pH 7.4) for 10 minutes, followed by 200 ml 4% ice-
cold paraformaldehyde in PBS for 20 minutes. Next, L5 spinal cord sections (thickness: 
10μm) were postfixed in paraformaldehyde at 4 °C for 24 hours. In brief, sections were 
pre-treated with 1% H2O2 in PBS for 15 minutes to minimize endogenous peroxidase 
activity, and then treated with 0.5% Triton X-100 in PBS, for 30 minutes, blocked in 2% 
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normal donkey antiserum, for 1 hour, and incubated in primary rabbit anti-BDNF 
serum (1:250; Cat Nr: ANT-010, Alomone, Jerusalem, Israel), for 16 hours. This was 
followed by 4x10-minute washes in PBS, and 2-hour incubation in secondary anti-
rabbit serum in a dilution of 1:200 (Cy3-conjugated anti rabbit IgG; Cat No: 711-165-
152; Jackson Immunoresearch Laboratories; West Grove, PA, USA). The high specificity 
of the anti-BDNF serum was confirmed by preabsorbing the antiserum with synthetic 
BDNF, which totally abolished immunostaining. In addition, omission of the primary 
antiserum completely prevented immunoreaction in all cases. 
3.2.7 Morphometry 
Sections were examined with a TCS-SP2-AOBS confocal laser-scanning microscope with 
a 20x/0.7 UV dry lens (Leica Microsystems, Wetzlar, Germany). Counts of BDNF-
immunoreactive structures in laminae I and II of the left (ipsilateral) and right dorsal 
horn were made on digital images taken at 1024x1024 dpi in the 3 most medial trans-
versal sections of the spinal cord, 75 μm apart, and processed with ImageJ 1.44 soft-
ware (National Institutes of Health, Bethesda, MA, USA). Earlier studies had shown 
that BDNF is present in both dorsal horns of untreated rats and does not increase in 
the contralateral dorsal horn upon CCI-surgery of the left sciatic nerve [16, 17]. The 
difference in BDNF-immunoreactive counts in the ipsilateral (left) and contralateral 
(right) dorsal horn served as a measure for the effect of CCI on spinal BDNF expression 
in the left dorsal horn. 
3.2.8 Statistics 
An experimenter unaware of the surgical and pharmacologic treatments of the animals 
performed all data acquisition. Statistical analyses were carried out using Prism 5.0d 
(GraphPad Software, San Diego, CA, USA). For each parameter, data were averaged for 
animals within an experimental group and expressed as means + standard error of the 
mean (SEM). Analysis of variance was used to examine behavioral changes in an animal 
group over time, as well as differences between drug-treated and control groups at the 
various sampling times. This was followed by Tukey’s post hoc test. Immunocytochem-
istry data were analyzed with Student’s unpaired 1-tailed t-test followed by Kolmogo-
rov-Smirnov’s post hoc analysis. All analyses were preceded by tests for normality 
(Shapiro and Wilk, 1965) and homogeneity of variance (Bartlett’s Chi-square test; 
Snedecor and Cochran, 1989). The threshold of significance was at α = 5%. 
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3.3 Results 
3.3.1 Induction of neuropathic pain by CCI 
The data from the behavioral studies are presented in Figures 1 and 2. Before surgery 
(BL; presurgery baseline) none of the rats in any group showed any sign of NP, neither 
in any of the behavioral tests for cold and heat hyperalgesia or for mechanical allo-
dynia. 
 In shams, no signs of NP behavior were observed throughout the experiment (Figs. 
1A-C). In shams, the frequency of left hind paw lifts (number in 5 minutes) on the cold 
plate BL (0.5±0.3) remained low and not significantly different from that on day 7 
(0.5±0.3), day 14 (2.8±2.8) and day 21 (0.7±0.4). A similar situation held for the latency 
(seconds) until hind paw withdrawal in the plantar test (day 7: 17.4±1 seconds; day 14: 
16.8±0.9 seconds; and day 21: 17.6±1 seconds vs. BL 17.4±1 seconds) and for the force 
needed for hind paw withdrawal with Von Frey filaments (day 7: 16.3±0.6 g; day 14: 
16.0±0.8 g; and day 21: 15.5±0.8 g vs. BL: 16.3±0.6 g). 
 In contrast, control animals that underwent CCI surgery followed by administra-
tion of 0.9% NaCl, unmistakably exhibited NP behavior in all 3 tests (Fig. 1A-C). Lift 
frequency on the cold plate was dramatically increased on day 7 (19.6±3.1; P≤0.001), 
day 14 (22.1±2.3; P≤0.001) and day 21 (16.6±3.8; P≤0.01) when compared with BL 
(0.3±0.3). Latency until left hind paw withdrawal decreased significantly for the dura-
tion of the experiment (day 7: 10.5±1.5 seconds; P≤0.001; day 14: 10.6±0.9 seconds; 
P≤0.001; and day 21: 8.8±0.9 seconds; P≤0.001 vs. BL: 17.2±0.9 seconds) as did the 
force needed for left hind paw withdrawal with Von Frey filaments (day 7: 14.1±0.3 g; 
P≤0.001; day 14: 13.3±0.3 g; P≤0.001; and day 21: 13.3±0.6 g; P≤0.001 vs. BL: 16.8±0.4 g). 
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Figure 1. (A) Number of left hind paw 
lifts in 5 minutes, in the cold plate test; 
(B) latency till withdrawal of the left 
hind paw in the plantar test; and (C)
force needed for withdrawal of this 
paw in the Von Frey test, at BL (pre-
surgery baseline), day 7 (start drug
administration) and at day 14 and day 
21 (after 7 and 14 days of drug 
administration, respectively). Means ± 
SEM. Sham (no sciatic CCI); n=6, 
control (sciatic CCI, 0.9% NaCl injec-
tion); n=8. ° P ≤ 0.01 and °° P ≤ 0.001 
compared with day 7 in the same 
group. 
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In the drug-treated groups, CCI also resulted in clear NP behavior in all 3 tests (Figs. 2A-
C). In the minocycline, amitriptyline and gabapentin groups there was a clear increase 
in lift frequency on day 7 compared with BL (17.4±0.6 vs. 0.4±0.3; P≤0.001; 21.5±2.6 
vs. 0.5±0.3; P≤0.001 and 17.2±1.7 vs. 1.0±0.9; P≤0.001, respectively). In the plantar 
test, time till left hind paw lift on day 7 decreased considerably compared with BL in 
the minocycline (14.1±1.4 vs. 18.2±0.6; P≤0.05), amitriptyline (11.0±1.3 vs. 17.4±0.8; 
P≤0.01) and gabapentin (10.2±1.7 vs. 16.9±0.4; P≤0.05) group. Finally, the force need-
ed for left hind paw lift with Von Frey filaments decreased in all 3 drug treated groups 
on day 7 compared with BL (minocycline: 15.2±0.6 vs. 16.6±0.3; P≤0.05; amitriptyline 
13.9±0.6 vs. 16.0±0.6; P≤0.05; gabapentin 14.1±0.3 vs. 16.9±0.4; P≤0.001). At no time 
point was any effect of CCI found on the unoperated right hind paw.  
3.3.2 Effect of drug treatment 
There was no statistical difference in the parameters of the behavioral tests at day 7 
between controls, amitriptyline-, gabapentin- or minocycline-treated rats. Control 
animals clearly exhibited cold and heat hyperalgesia and mechanical allodynia, which 
persisted throughout the experiment (Figs 1A-C). Whereas on day 21 there was a 
spontaneous reduction in the number of lifts on the cold plate, this did not reach 
statistical significance compared with day 7. In the plantar test and Von Frey test there 
were no signs of spontaneous recovery. 
 Behavioral results from the minocycline, amitriptyline and gabapentin groups are 
presented in Figs. 2A-C. Minocycline-treated animals demonstrated progressively 
decreasing cold hyperalgesia in the cold plate test during the 2 weeks of drug therapy. 
The number of lifts on the cold plate was significantly reduced on day 14 (9.2±1.9; 
P≤0.05) and day 21 (6.6±1.3; P≤0.001) when compared with day 7 (17.4±2.6). Also on 
days 14 and 21 when compared with control animals, rats in the minocycline group 
lifted considerably less (22.1±2.3 vs. 9.2±1.9; P≤0.01 and 16.6±3.8 vs. 6.6±1.3; P≤0.05 
respectively). The latency until left hind paw withdrawal in the plantar test was reduced 
on day 21 when compared with control (8.8±0.9 seconds vs. 14.3±1.4 seconds; P≤0.05). 
In the Von Frey test minocycline failed to reverse mechanical allodynia at any time point 
(day 14: 14.1±0.7 g; P>0.05; day 21: 14.3±0.8 g; P>0.05 vs. day 7: 15.2±0.6 g). 
 Amitriptyline progressively diminished cold hyperalgesia during the experiment. 
On day 21 the number of lifts on the cold plate was lower than on day 7 (14.4±2.1 vs. 
21.5±2.6; P≤0.05). However, in the plantar and Von Frey tests amitriptyline-treated 
animals showed no improvement in NP behavior. 
 Although there was a clear trend for gabapentin to reduce the number of lifts on 
the cold plate, the different means did not reach statistical significance. The same held 
for heat hyperalgesia and mechanical allodynia during the 2 weeks of drug treatment. 
At no time point was any effect of drug treatment found on the unoperated right hind 
paw. 
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Figure 2. (A) Number of left hind paw 
lifts in 5 min, in the cold plate test; (B)
latency till withdrawal of the left hind 
paw in the plantar test; and (C) force 
needed for withdrawal of this paw in 
the Von Frey test, at BL (pre-surgery 
baseline), day 7 (start drug administra-
tion) and at day 14 and day 21 (after 7 
and 14 days of drug administration, 
respectively). Minocycline-treated
(n=9), amitriptyline-treated (n=8), 
gabapentin-treated (n=9) rats. Means 
± SEM. * P ≤ 0.05 and ** P ≤ 0.01, 
compared with the corresponding day 
in the control group (n=8). ° P ≤ 0.05 
and °°P ≤ 0.001 compared with day 7 
in the same group. 
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Figure 3. Immunocytochemistry of BDNF-immunoreactive structures in the dorsal horn of a control (no drug 
treatment) CCI rat, with stronger immunoreactivity in the left horn (A) than in the right one (B). After drug 
treatment immunoreactivity is lower in minocycline group (E) than in amitriptyline (C) and gabapentin (D) 
groups. 
 
3.3.3 BDNF-immunoreactivity in the dorsal horn 
Sections revealed clear BDNF immunoreactivity in the dorsal horns of control- and 
drug-treated animals, which was mainly located in laminae I and II (Fig. 3). When 
compared with control (918±287), only minocycline reduced the number of BDNF-
immunoreactive structures in the left dorsal horn (369±104; P≤0.05). Although the 
number of BDNF-immunoreactive structures was lower in both the amitriptyline 
(529±125) and gabapentin (641±155) group compared to the control group, this did 
not reach statistical significance (Fig. 4). 
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Figure 4. Quantification of BDNF-immunoreactivity in the left dorsal 
horn. Means ± SEM. C indicates control (n=4); A, amitriptyline (n=4); G, 
gabapentin (n=6); M, minocycline (n=5). * P ≤ 0.05, compared with
control group. 
3.4 Discussion 
In the present study, we demonstrated the effectiveness of minocycline and amitripty-
line in reducing thermal hyperalgesia when started 7 days after a sciatic CCI. The 
effects were more pronounced in the minocycline group than in the amitriptyline 
group whereas neither of these drugs could reverse CCI-induced mechanical allodynia. 
Surprisingly, when administered 7 days after CCI, gabapentin had no effect on either 
thermal hyperalgesia or mechanical allodynia. After 2 weeks of drug treatment, mino-
cycline but not amitriptyline or gabapentin reduced BDNF-immunoreactivity in the 
ipsilateral dorsal horn. 
 Our behavioral data on the effects of minocycline on NP concur with earlier short-
term (7 days) studies where preemptive administration of minocycline was effective in 
reducing NP behavior in rodent sciatic CCI [7-9]. However, the present study is the first 
to demonstrate a long-lasting effect (up to 21 days post-injury) of minocycline when 
administered 7 days after CCI instead of preemptively. This profile neatly fits the 
clinical situation because patients consult their physicians after the emergence of NP, 
making preemptive drug administration impossible, and because chronic administra-
tion is often required. However, to date, no clinical trials have been conducted to 
assess the effect of minocycline on NP in humans. Although effectively reducing 
thermal hyperalgesia in our CCI rats, minocycline had no effect on mechanical allo-
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dynia when administered 7 days post-injury. A similar outcome was observed in a 
spinal nerve ligation model [18] where administration of minocycline from day 7 
forwards had no appreciable effect on mechanical allodynia. However, when adminis-
tered on day 1 or day 3, minocycline substantially reversed mechanical allodynia 
(47.7% and 24.9% reduction of paw withdrawal threshold, respectively) indicating that 
the therapeutic window for minocycline to reverse mechanical allodynia after CCI 
surgery is limited to 3 days, whereas for thermal hyperalgesia this window is at least 7 
days. The mechanism underlying the differential actions of minocycline on mechanical 
vs. thermal hyperalgesia deserves further research.  
 In previous animal studies preemptively administered amitriptyline was effective 
in reducing NP in a spared nerve injury model and in a spinal nerve ligation model [11, 
19]. Yet, clinical data about the preemptive effect of amitriptyline are conflicting 
because trials revealed positive as well as negative outcomes [20, 21]. In our study, 
amitriptyline was effective in reducing cold hyperalgesia when started 7 days after CCI. 
However, because amitriptyline was less effective than minocycline, minocycline may 
be more appropriate for use in a clinical setting where drug application starts after 
emergence of NP. Nevertheless, like minocycline, amitriptyline was unable to reverse 
mechanical allodynia in our study. Pradhan et al. [22] found identical results on me-
chanical allodynia in a CCI and spinal nerve ligation model when amitriptyline was 
administered 7 days post-injury. It is possible that the therapeutic window for amitrip-
tyline for reversal of mechanical allodynia is, as for minocycline, smaller than 7 days. 
 Here we have demonstrated that gabapentin only reveals a trend towards reduc-
ing cold hyperalgesia without reaching statistical significance. In other animal studies 
gabapentin was able to reduce NP behavior when given preemptively and post-injury 
[12, 22]. The results of our animal study are in line with a multicenter clinical trial 
investigating the effects of gabapentin in traumatic nerve injury pain. After gabapentin 
treatment for 5 weeks, the authors found no decrease in mean pain intensity score. 
This could point to a greater clinical relevance of our study paradigm compared to 
short-term studies with preemptive drug administration to investigate drug effects on 
traumatic nerve injury [23]. 
 The reduced NP behavior after 14 days of minocycline administration was accom-
panied by markedly reduced spinal BDNF expression in the ipsilateral dorsal horn. 
These findings are in line with those of Miletic and Miletic [3] who found a positive 
time correlation between spinal BDNF concentration and emergence and disappear-
ance of thermal hyperalgesia in rats. Further studies confirming the importance of 
BDNF in the pathophysiology of NP are those in which BDNF was sequestered by 
intrathecal application of BDNF-antiserum or of TrkB/fc fragments or by inhibiting the 
TrkB receptor by K-252a thus preventing the development of thermal hyperalgesia in 
animal CCI models [24, 25]. These data suggest that minocycline exerts its analgesic 
effects through a BDNF-dependent mechanism whereas for amitriptyline other mech-
anisms prevail [11, 19]. In our experiment, we did not explore the mechanism by which 
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minocycline reduces BDNF expression in the dorsal horn, but the literature suggests an 
involvement of mitogen-activated protein kinase pathways [18]. 
 In conclusion, this study adds to our current knowledge of BDNF expression, NP, 
and its treatment, by demonstrating that amitriptyline and gabapentin, drugs currently 
used for the treatment of NP, do not exert their analgesic effect through a BDNF-
dependent pathway as opposed to minocycline. Moreover, our study reveals that 
minocycline more than amitriptyline has a long-lasting effect on NP behavior not only 
when administered pre-emptively but also when administered after the establishment 
of NP. This finding is clinically relevant since most patients consult their physician after 
the development of NP. Future investigations should focus on the combined effects of 
drugs with different modes of action and on validating the results of the animal studies 
involving minocycline in clinical practice. 
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Abstract 
Background 
Less than 50% of patients experience sufficient pain relief with current drug therapy 
for neuropathic pain. Minocycline shows promising results in rodent models of neuro-
pathic pain but was not yet studied in humans with regard to the treatment of neuro-
pathic pain. 
Methods 
In this randomized, double-blind, placebo-controlled clinical trial, patients with sub-
acute lumbar radicular pain received placebo, amitriptyline 25mg or minocycline 
100mg once a day (n=20 per group) for 14 days. Primary outcome measure was the 
pain intensity in the leg as measured by a numeric rating scale (NRS) ranging from 0 to 
10 on days 7 and 14. Secondary outcome measures were reduction of neuropathic 
pain symptoms in the leg as determined with the DN4 questionnaire, consumption of 
rescue medication and adverse events on days 7 and 14. 
Results 
Sixty patients were randomized and included in an intention-to-treat analysis. After 14 
days, patients in the minocycline and amitriptyline groups reported a reduction of 1.47 
(95% confidence interval: 0.16-2.83, P=0.035) and 1.41 (95% confidence interval 0.05-
2.78, P=0.043), respectively in NRS score compared to the placebo group. No differ-
ences were seen in DN4 values at any time point during treatment between the 3 
groups. The rate of adverse events in the amitriptyline group was 10% vs. none in the 
minocycline and placebo groups. No differences were noted in the consumption of 
rescue medication. 
Conclusion 
These short-term outcomes suggest that minocycline and amitriptyline are equally 
effective in treating lumbar radicular neuropathic pain and warrant additional larger 
trials. 
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4.1 Introduction 
Chronic pain imposes a heavy burden on patients and society. With an annual cost of 
US$ 560 billion, the expenditure of pain in the United States exceeds these of cancer, 
heart disease and diabetes combined [1]. Neuropathic pain, defined as pain arising 
from a lesion within the somatosensory nervous system [2], is one of the most debili-
tating forms of chronic pain. Although neuropathic back and leg pain are the most 
common forms of neuropathic pain [3], they are the least researched with regard to 
drug efficacy. Amitriptyline for instance, is a tricyclic antidepressant and first-line drug 
in the treatment algorithm of neuropathic pain [4] but was never studied in patients 
with lumbar radicular pain. Furthermore, efficacy of a drug for a particular type of 
neuropathic pain cannot be extrapolated to another type of neuropathic pain [5-7] 
and, moreover, first-line therapies for neuropathic pain are often accompanied by 
considerable side effects, limiting their usability [8-10]. Consequently, there is a strong 
need for studies with accepted first-line drug therapies in patients with lumbar radicu-
lar pain as well as for novel drugs to treat neuropathic pain. 
 Minocycline is a semisynthetic tetracycline with antibiotic action against a wide 
range of gram-positive, gram-negative and atypical micro-organisms. It attenuates 
mechanical allodynia and thermal hyperalgesia in rodent models of neuropathic pain 
when administered pre-emptively [11, 12] and post-injury [13], mainly through micro-
glial inhibition and decreased expression of brain-derived neurotrophic factor [11, 13]. 
Beneficial effects of minocycline have been observed in the neurological and functional 
recovery of patients with stroke [14], spinal cord injury [15] and multiple sclerosis [16]. 
A first indication that minocycline can improve neuropathic pain, was recently ob-
tained by Syngle et al [17] in patients suffering from polyneuropathy associated with 
type 2 diabetes. With the present study we aim to confirm and extend their observa-
tion by testing the effect of minocycline on lumbar radicular neuropathic pain. Since in 
humans, minocycline is readily absorbed by the gastro-intestinal tract [18] and easily 
crosses the blood-brain barrier with cerebrospinal fluid levels ranging between 25 and 
30% of serum concentrations [19], oral administration of this drug is suitable to treat 
central nervous system diseases. 
 In the present randomized, double-blind, placebo-controlled clinical trial with 
amitriptyline as a comparator, we are the first to test the hypothesis that minocycline 
reduces neuropathic pain in patients suffering from lumbar radicular pain. Since we 
performed this trial as a proof of concept study, we choose the smallest number of 
participants needed based on our power analysis together with a relatively short 
follow-up period of 2 weeks in order not to withhold patients from other treatments. 
The primary objective of this study was to analyze the effect of minocycline on pain 
intensity as compared to placebo and amitriptyline. Secondary outcome measures 
included assessment of neuropathic pain symptoms, consumption of rescue medica-
tion, and possible adverse events. This study was part of a larger clinical trial that 
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included determination of plasma and serum concentrations of brain-derived neu-
rotrophic factor in patients with lumbar radicular pain (clinicaltrials.gov number 
NCT01869907). 
4.2 Methods 
4.2.1 Study design and settings 
In this single centre, randomized, double-blind, placebo-controlled, clinical trial with 
amitriptyline as an active comparator, we investigated the effect of minocycline on 
neuropathic lumbar radicular pain. The trial was conducted at the Ziekenhuis Oost-
Limburg in Genk, Belgium and was approved by the local ethics committee (Commissie 
voor Medische Ethiek) and registered at clinicaltrials.gov (trial number: NCT01869907). 
The study started in September 2011 and ended in August 2013 when the objective of 
60 enrolled patients had been reached. 
4.2.2 Participants 
Patients were recruited by means of physician referrals to our tertiary multidisciplinary 
pain clinic at the Ziekenhuis Oost-Limburg in Genk, Belgium. Eligible patients presented 
with lumbosacral radicular pain radiating into the leg below the knee caused by disc 
herniation, spinal canal stenosis or failed back surgery syndrome. Patients were in-
cluded only if the level of the pathology on CT- or MR-imaging correlated with the 
dermatome in which they indicated their leg pain and if the leg pain was predominant 
over the back pain (NRS score for leg pain > NRS score for back pain). The dermatomal 
distribution of the leg pain was determined with the adapted dermatomal map from 
Wolff et al [20]. The neuropathic nature of the leg pain was determined by a validated 
Dutch translation of the douleur neuropathique (DN4) questionnaire (cut-off ≥ 4) [21]. 
The in- and exclusion criteria are presented in Table 1. All patients gave written in-
formed consent before inclusion in the study. 
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Table 1. In- and exclusion criteria of the study 
Inclusion criteria: Exclusion criteria
Age 18 to 80 years Diabetic, alcoholic or drug induced 
polyneuropathies 
Neuropathic lumbar radicular pain caused by: Depression or psychiatric comorbidity affecting 
pain sensation 
Lumbar disc herniation, spinal canal stenosis or failed back 
surgery syndrome (epidural fibrosis) confirmed by CT- or 
MR-imaging 
Use of antidepressants
Level of pathology on imaging studies correlates with 
dermatomal distribution in the leg 
Fibromyalgia and chronic fatigue syndrome 
Pregnancy 
Spinal cord damage 
Malignancy 
Allergy for minocycline or amitriptyline 
CT: computer tomography; MR: magnetic resonance.
 
4.2.3 Interventions 
Sixty patients were randomized in a 1:1:1 ratio to receive once daily, during 2 weeks, 
either placebo (starch; Fagron, Waregem, Belgium), amitriptyline 25mg (Aca Pharma, 
Waregem, Belgium) or minocycline 100mg (ABC Chemicals, Wouters-Brakel, Belgium). 
Patients were instructed to take the study medication in the morning with a glass of 
water one hour before or one hour after breakfast, to prevent interference of food 
with gastro-intestinal absorption with the study drug [18]. Continuation of paraceta-
mol or non-steroidal anti-inflammatory drugs was permitted during the trial period on 
the condition that patients were on a stable dose for at least 1 week prior to enrol-
ment. Otherwise, the only pain medications permitted during the trial period were the 
study drug and rescue medication. Rescue medication consisted of 50mg tramadol 
(Tradonal Odis; Meda Pharma, Brussels, Belgium) with a maximum of 3 intakes daily 
and 6h between consecutive ingestions. During the trial period patients completed 3 
study visits: a baseline visit and visits after 7 and 14 days during which the pain intensi-
ty in the leg measured by a 11-point numeric rating scale (NRS) and DN4 score was 
obtained, and a supply for 1 week of trial (7 capsules) and rescue medication (21 
tablets) was provided. During visits 2 and 3 patients were asked if they experienced 
any adverse events. Drug logs were kept to record the amount of rescue medication 
the patients had consumed during the past week and to record if the patients had 
taken the entire amount of investigational drugs. 
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4.2.4 Outcome measures 
The primary outcome measure was the effect on pain intensity in the leg. Patients 
were asked to rate their average leg pain during the past 24h on an 11-point NRS with 
0 indicating no pain and 10 the worst pain imaginable [22]. Secondary outcome 
measures were changes in neuropathic pain symptoms in the leg (burning pain sensa-
tion, cold painful sensation, electric shocks, paresthesia, ‘pins and needles’ sensation, 
numbness, itching pain sensation, hypoesthesia to touch, hypoesthesia to pinprick and 
mechanical allodynia, with a score of 1 awarded for every symptom present) as meas-
ured with the DN4 [21], changes in consumption of rescue medication and adverse 
events. The assessments were made at baseline (visit 1) and after 7 (visit 2) and 14 
days (visit 3) for the NRS and DN4 scores and during visits 2 and 3 for consumption of 
rescue medication and adverse events. In order to detect adverse events, patients 
were asked on days 7 and 14 of the trial if they had experienced side-effects during the 
past week attributable to the study drugs. 
4.2.5 Blinding and randomization 
A hospital pharmacist prepared study kits containing the study drug and rescue medi-
cation for each patient for the entire duration of the study and randomly assigned a 
number to each kit ranging from 1 to 60. Each kit contained 2 white vials labeled ‘study 
medication’, each vial containing 7 capsules and 2 white vials labeled ‘rescue medica-
tion’, each vial containing 21 tablets of 50mg tramadol. The encryption key linking the 
numbers of each kit to its content was safeguarded by the pharmacist until the end of 
the study and was unknown to all the outcome assessors. Placebo, amitriptyline and 
minocycline were encapsulated in identical opaque white capsules so that patients and 
study staff were unable to visually distinguish their contents. Upon inclusion, patients 
were randomized by assigning them a study kit number by a computerized random 
number generator. 
4.2.6 Statistical methods 
A decrease of 2 or more points on an 11-point NRS has been shown to be moderately 
clinically meaningful [23]. In order to detect this difference with a standard deviation 
of 1.7 [24] and a power of 90% with a significance level set α = 0.05, we calculated that 
a sample size of 16 patients per group would be needed [25]. In order to compensate 
for an estimated dropout rate of 20% we included 20 patients per group. An intention-
to-treat analysis was performed with none of the patients excluded because of missing 
data. To determine the effect of placebo, amitriptyline 25mg and minocycline 100mg 
on NRS and DN4 scores, we used a linear regression model with time in weeks, the 
baseline value of the outcome, dummies for the active interventions and an interac-
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tion between time and the intervention dummies as covariates. The 2 interaction 
terms were entered to estimate the change over time for the different interventions. A 
random intercept model was used to take into account the statistical dependence of 
the measurements. A mixed model analysis of variance with Bonferroni’s post-hoc test 
was used to assess changes in consumption of rescue medication. Finally, a cumulative 
proportion responder analysis [26], which displays the level of response at all possible 
cut-off points, was performed for NRS and DN4 scores on day 14. The cut-off points 
are the percent change in NRS pain intensity or DN4 score respectively, on day 14 
compared to day 1 (e.g. 50% signifies that the NRS score or DN4 score has halved on 
day 14). Data are presented as means ± standard error of the mean (SEM). Statistical 
analyses were carried out using IBM SPSS version 20, release 20.0.0.1 (Armonk, NY, 
USA). 
4.3 Results 
4.3.1 Study population 
Sixty patients were randomized, 20 to each treatment group. Nine patients (3 patients 
per study arm) discontinued the trial in the first week, 2 because of violation of the 
study protocol (one patient took the study medication for 2 days and then switched to 
non-steroidal anti-inflammatory drugs, the other patient stopped study medication 
after 2 days without giving a reason), 2 because of adverse effects (both in the amitrip-
tyline group) and 5 patients withdrew their informed consent. In total 51 patients (17 
per treatment arm) completed the study (Fig. 1). The baseline characteristics were 
similar across the 3 study arms (Table 2). 
4.3.2 Primary outcome 
All patients were included in the regression analysis. After 2 weeks of therapy, patients 
in the minocycline and amitriptyline groups reported a reduction of 1.47 (95% confi-
dence interval: 0.16-2.83, P=0.035) and 1.41 (95% confidence interval 0.05-2.78, 
P=0.043) in NRS score, respectively, compared to the placebo group. There was no 
statistically significant difference in NRS score between the minocycline and amitripty-
line group after 2 weeks of therapy (Fig. 2 panel A). The cumulative proportion re-
sponder analysis at day 14 showed more responders in the minocycline and amitripty-
line group than in the placebo group for all cut-off points (Fig. 2 panel B). The number 
needed to treat (NNT) for moderate (≥30%) and substantial (≥50%) clinically important 
improvements in NRS score [27] are 3 and 6 for minocycline and 3 and 4 for amitripty-
line, respectively.  
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Figure 1. CONSORT flowchart. 
OD: once daily. 
 
Table 2. Demographic data and baseline characteristics of the patients 
Characteristic Placebo
 (n=20) 
Amitriptyline
 (n=20) 
Minocycline 
 (n=20) 
Age - yr 51±3 50±3 47±3
Sex - no. (%) 
Male 9 (45) 13 (65) 11 (55) 
Female 11 (55) 7 (35) 9 (45) 
Culprit nerve root - no. (%) 
L3 0 (0) 2 (10) 1 (5)
L4 3 (15) 1 (5) 7 (35) 
L5 8 (40) 6 (30) 8 (40) 
S1 9 (45) 11 (55) 4 (20) 
Cause of neuropathic pain - no. (%) 
Disc herniation 16 (80) 16 (80) 17 (85) 
Spinal canal stenosis 4 (20) 2 (10) 1 (5)
Failed back surgery syndrome 0 (0) 2 (10) 2 (10) 
Duration of pain - mo 2.8±0.4 3.2±0.6 2.5±0.3 
NRS score 7.4±0.3 6.9±0.4 7.1±0.4 
DN4 score 4.2±0.4 4.3±0.4 4.9±0.3 
Plus-minus values are means±SEM. NRS: numeric rating scale ranging from 0 to 10 for leg pain; higher scores 
indicate more pain. DN4: douleur neuropathique questionnaire, scores ranging from 0 to 10; higher scores 
indicate more neuropathic pain symptoms are present. Cut-off for the presence of neuropathic pain is a 
score ≥ 4. 
T H E  E F F E C T  O F  M I N O C Y C L I N E  O N  L U M B A R  R A D I C U L A R  N E U R O P A T H I C  P A I N  
 73
Figure 2. Primary outcome measures 
Panel A. Patient’s assessment of pain intensity 
NRS: numeric rating scale ranging from 0 to 10 for leg pain. Higher scores indicate more pain. 
* P<0.05 for NRS score in the minocycline and amitriptyline group compared to placebo on day 14. Panel B.
Cumulative proportion responder analysis for mean daily pain intensity in the leg on day 14 as measured by
the NRS. X-axis: level of response (% improvement) in mean daily pain intensity from baseline NRS score on
day 14. Y-axis: proportion of patients (%) that equal or exceed the level of response. 
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4.3.3 Secondary outcomes 
With respect to DN4 scores, 2 weeks therapy resulted in decrease of 1.26 points (95% 
confidence interval: -0.01-2.25, P=0.053) and 0.35 points (95% confidence interval: -
0.8-1.48, P=0.54) in the amitriptyline and minocycline group, respectively, compared to 
placebo. Cumulative proportion responder analysis of neuropathic symptoms also 
showed closely matched responder curves for amitriptyline, minocycline and placebo, 
indicating no obvious differences between the 3 treatment groups (Fig. 3). There were 
no statistically significant differences in the consumption of rescue medication be-
tween the 3 groups at any time point (Table 3). 
 
 
 
Figure 3. Cumulative proportion responder analysis for neuropathic pain symptoms in the 
leg on day 14 as measured by the DN4. X-axis: level of response (% improvement) in 
neuropathic pain symptoms from baseline on day 14. Y-axis: proportion of patients (%) that 
equal or exceed the level of response. 
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Table 3. Secondary outcome measures 
 DN4 score Rescue medication
 Baseline Day 7 Day14 Week 1 Week 2 
Placebo 4.2±0.4 3.7±0.5 3.6±0.6 12±2 12±2 
Minocycline 4.9±0.3 4.2±0.5 3.9±0.5 11±2 14±2 
Amitriptyline 4.3±0.4 2.9±0.4 2.2±0.3 9±2 9±2 
Plus-minus values are means±SEM. DN4: douleur neuropathique questionnaire;
higher scores indicate more neuropathic pain symptoms are present. Cut-off for the presence of neuropathic 
pain is a score ≥ 4, scores ranging from 0 to 10. 
Rescue medication is the number of 50mg tramadol tablets taken over the course of the past week.  
No statistically significant differences in DN4 score or amount of rescue medication were noted between the 
three treatment groups at any time point. 
 
4.3.4 Adverse events 
In the amitriptyline group, 2 out of 20 patients (10%) reported adverse events within 
the first week of treatment. One patient complained of nausea, vomiting and a general 
unwell feeling, and a second patient developed a rash. All symptoms disappeared after 
discontinuation of the study medication. No adverse events were reported in the 
placebo and minocycline groups. 
4.4 Discussion 
The results from this study suggest that minocycline and amitriptyline improve lum-
bosacral radicular pain for at least 2 weeks and, furthermore, that treatment with 
minocycline is associated with less adverse events compared to amitriptyline. After 2 
weeks of treatment, minocycline and amitriptyline reduced pain intensity by 1.47 and 
1.41 points on the NRS, respectively. This result was not caused by differences in the 
amount of rescue medication taken in the different groups. The placebo response for 
moderate improvement in NRS score was 18% in our study, approximating the placebo 
response of other neuropathic pain trials in a Cochrane review [9]. With this result we 
not only support the conclusion made by Syngle et al [17] that minocycline reduces 
neuropathy but extend it to lumbar radicular pain. 
 To date, no other studies are available on the use of minocycline for the primary 
treatment of lumbar radicular neuropathic pain in humans. In one study, researchers 
investigated the preventive effect of minocycline on persistent pain after lumbar 
discectomy [28]. Minocycline was administered perioperatively for 8 days, but failed to 
reduce the incidence of low back and leg pain 3 months after surgery. However, a 
subgroup analysis in the latter study suggested that patients with similar symptoms as 
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the patients in our study (predominant deep spontaneous neuropathic leg pain) might 
benefit from minocycline treatment. Another study concerned the effect of a single 
dose of minocycline on neuropathic pain induced by an intradermal capsaicin injection 
in patients with unilateral sciatica, which showed no significant effect on NRS score 
[29]. The negative results in both these studies could be related to the timing and 
duration of minocycline administration since in our study the antinocicepive effect of 
minocycline only became apparent after 2 weeks of treatment. 
 In our study, minocycline shows a reduction in pain intensity with similar NNT’s 
compared to amitriptyline, a first-line drug for the treatment of neuropathic pain. We 
found no randomized studies concerning amitriptyline and radicular neuropathic pain, 
but our NNT values for amitriptyline match those found in a systematic review by 
Moore et al. where the effects of amitriptyline on painful diabetic neuropathy, post-
herpetic neuralgia, post-stroke pain and fibromyalgia were pooled [9]. Our data are in 
contrast with a study by Khomori et al. [5] where nortriptyline, an active metabolite of 
amitriptyline and also a first-line drug for the treatment of neuropathic pain, failed to 
improve chronic lumbar radicular pain. Two important differences between our study 
and the study of Khomori can provide an explanation for these opposing outcomes of 
two almost identical drugs. First, there is a different time interval to treatment: in our 
study patients had a mean duration of pain of approximately 3 months while in the 
study by Khomori and colleagues the median duration of pain was 5 years. It is known 
that pain becomes less responsive to treatment the longer it persists [30]. Whether 
this effect is due to consolidation of pathophysiologic processes, rendering neuro-
pathic pain less responsive to drug treatment over time or due to acquired overlying 
psychosocial issues and psychopathology in patients with chronic pain, resulting in 
lower response rates for treatments remains to be elucidated. Second, there is a 
different timing in administration of the tested drugs: in our study amitriptyline was 
administered in the morning whereas nortriptyline in the study by Khomori was ad-
ministered in the evening. Chronopharmacology studies showed significant higher 
serum concentrations of amitriptyline when administered in the morning than in the 
evening due to a higher absorption rate constant and a shorter time to peak concen-
tration [31]. This can also account for the fact that we found a significant clinical effect 
with relative low doses of amitriptyline. 
 In a randomized controlled trial [32] and in a systematic review [33], combination 
therapy for neuropathic pain (tricyclic antidepressants or antiepileptics combined with 
opioids and nortriptyline or gabapentin alone or combined, respectively) was found 
beneficial over monotherapy. However, the usability of combination therapy is often 
limited due to overlapping side-effects of the drugs. The absence of adverse events 
associated with minocycline treatment (vs. 10% in the amitriptyline group) in our 
study, suggests that minocycline could be useful in combination therapy. The adverse 
event rate of 10% we noticed in the amitriptyline group, was lower than the 64% 
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previously reported in a systematic review [9] probably because of the short duration 
of our trial and the relatively low dose of amitriptyline we used. 
 The limitations of our study are related to the short follow-up period and a rela-
tive small number of participants. However, the optimal timing of, and duration for the 
treatment of neuropathic pain in humans with minocycline is unknown and our power 
calculation was effective in predicting the amount of patients needed to detect a 
significant drop in pain intensity. The dosages of minocycline (100mg daily) and ami-
triptyline (25mg daily) we used, were lower than reported in other studies [9, 28] but 
in view of the fact that neuropathic pain often requires long-term treatment, the 
lowest dose of a drug with a clinically ample effect should be used, especially because 
25mg amitriptyline already impairs daily functions such as car driving [34]. Since 
potentially serious side-effects have been reported with the use of minocycline [35], 
larger studies with more detailed safety assessments are needed to determine the 
definite risk-benefit profile of this drug for the treatment of neuropathic pain. Finally, 
future studies may benefit from keeping a pain diary of NRS scores over a 24h period. 
 In conclusion, our short-term results suggest that minocycline and amitriptyline 
are equally effective in treating lumbar radicular neuropathic pain and, moreover, that 
treatment with minocycline is associated with fewer side-effects. This study warrants 
additional clinical trials with larger patient populations, longer follow–up and more 
intricate designs (e.g. crossover) to evaluate long-term outcome and safety and to 
study the effects of minocycline on other neuropathic pain conditions. 
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Abstract 
Occipital neuralgia is defined as a paroxysmal shooting or stabbing pain in the derma-
tomes of the nervus occipitalis major and/or nervus occipitalis minor. The pain origi-
nates in the suboccipital region and radiates over the vertex. A suggestive history and 
clinical examination with short-term pain relief after infiltration with local anesthetic 
confirms the diagnosis. No data are available about prevalence or incidence of this 
condition. Most often trauma or irritation of the nervi occipitales causes the neuralgia. 
Imaging studies are necessary to exclude underlying pathological conditions. Initial 
therapy consists of a single infiltration of the culprit nervi occipitales with local anes-
thetic and corticosteroids (2 C+). The reported effects of Botulinum toxin A injections 
are contradictory (2 C±). Should injection of local anesthetic and corticosteroids fail to 
provide lasting relief, pulsed radiofrequency treatment of the nervi occipitales can be 
considered (2 C+). There is no evidence to support pulsed radiofrequency treatment of 
the ganglion spinale (dorsal root ganglion) C2. As such this should only be done in a 
clinical trial setting. Subcutaneous occipital nerve stimulation can be considered if prior 
therapy with corticosteroid infiltration or pulsed radiofrequency treatment failed or 
provided only short-term relief (2 C+). 
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5.1 Introduction 
This review on occipital neuralgia is part of the series “Evidence-based Interventional 
Pain Medicine According to Clinical Diagnoses”. Recommendations formulated in this 
article are based on “Grading strength of recommendations and quality of evidence in 
clinical guidelines” described by Guyatt et al., and adapted by van Kleef et al. in the 
editorial accompanying the first article of this series [1,2](Table 1). 
 The latest literature update was performed in November 2009. 
 
Table 1. Summary of evidence scores and implications for recommenda-
tions 
Score Description Implications
1 A + Effectiveness demonstrated in various RCT's of good quality. The 
benefits clearly outweigh risk and burdens. 
} Positive recommendation 
1 B + One or more RCT's with methodological weaknesses, demonstrate 
effectiveness.  
The benefits clearly outweigh risk and burdens. 
2 B + One or more RCT's with methodological weaknesses, demonstrate 
effectiveness.  
The benefits closely balanced with risk and burdens. 
2 B ± Multiple RCT's with methodological weaknesses, yield contradictory 
results better or worse than the control treatment. 
Benefits closely balanced with risk and burdens, or uncertainty in the 
estimates of benefits, risk and burdens. } Considered, preferably  study-related 
2 C + Effectiveness only demonstrated in observational studies. 
Given that there is no conclusive evidence of the effect, benefits 
closely balanced with risk and burdens. 
0 There is no literature or there are case reports available, but these 
are insufficient to suggest effectiveness and/or safety.  
These treatments should only be applied in relation to studies. } Only study-related 
2 C − Observational studies indicate no or too short-lived effectiveness. 
Given that there is no positive clinical effect, risk and burdens 
outweigh the benefit. 
} Negative recommendation 
2 B − One or more RCT's with methodological weaknesses, or large 
observational studies that do not indicate any superiority to the 
control treatment. Given that there is no positive clinical effect, risk 
and burdens outweigh the benefit. 
2 A − RCT of a good quality which does not exhibit any clinical effect. 
Given that there is no positive clinical effect, risk and burdens 
outweigh the benefit. 
RCT: randomized controlled trial 
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The International Headache Society (IHS) defines occipital neuralgia as paroxysmal 
shooting or stabbing pain in the dermatomes of the nervus occipitalis major or nervus 
occipitalis minor [3]. The pain originates in the suboccipital region and radiates over 
the vertex. Hypo- or dysesthesia in the affected area can accompany the pain. Pressure 
over the nervus occipitalis major or minor usually elicits the pain. 
 No data are available about the prevalence or incidence of occipital neuralgia. The 
nervus occipitalis major is more frequently involved (90%) as compared to the nervus 
occipitalis minor (10%). In 8.7%, both nervi occipitales are responsible for the neuralgia [4]. 
 Often damage or irritation of the nervus occipitalis major or minor is the cause of 
the neuralgia. Vital et al. [5] described 2 bends that divide the course of the nervus 
occipitalis major into 3 parts. The nervus occipitalis major is formed by the ramus 
dorsalis of the C2 nerve root. The first part runs between the origin of the nerve and 
the musculus obliquus capitis inferior underneath which the nerve makes its first bend 
in a medial direction. The second part of the nerve runs cranially between the muscu-
lus semispinalis capitis on the one side and the musculus obliquus capitis inferior, 
musculus rectus capitis posterior and the musculus rectus capitis anterior on the other 
side. When perforating the musculus semispinalis capitis toward the surface, the nerve 
makes its second bend in a lateral direction. The third part of the nerve runs further 
laterally where the aponeurosis of the musculus trapezius is perforated and the nerve 
begins its subcutaneous course. The nervus occipitalis major usually branches after 
perforating the aponeurosis. 
 There are various potential causes of irritation: vascular, neurogenic, muscular 
and osteogenic. 
 
Vascular: 
• Irritation of the nerve roots C1/C2 by an aberrant branch of the arteria inferior 
posterior cerebelli (posterior inferior cerebellar artery) [6] 
• Dural arteriovenous fistula at the cervical level [7] 
• Bleeding from a bulbocervical cavernoma [8] 
• Cervical intramedullar cavernous hemangioma [9] 
• Giant cell arteritis [10-12] 
• Fenestrated arteria vertebralis pressing on C1/C2 nerve roots [13] 
• Aberrant course of the arteria vertebralis [14] 
Neurogenic: 
• Schwannoma in the area of the craniocervical junction: schwannoma of the nervus 
occipitalis [15,16] 
• C2 myelitis [17] 
• Multiple sclerosis [18] 
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Muscular/tendinous [19] 
Osteogenic: 
• C1/C2 arthrosis, atlantodental sclerosis [20] 
• Hypermobile arcus posterior of the atlas [21] 
• Cervical osteochondroma [22] 
• Osteolytic lesion of the cranium [23] 
• Exuberant callus formation after fracture C1/C2 [24] 
5.2 Diagnosis 
5.2.1 History 
Patients complain of a shooting or stabbing pain in the neck radiating over the crani-
um. Constant pain can persist between the paroxysms. The pain can be perceived in 
the retro-orbital area caused by overlap of the C2 dorsal root and the nucleus trigemi-
nus pars caudalis [25]. Vision impairment/ocular pain (67%), tinnitus (33%), dizziness 
(50%), nausea (50%), congested nose (17%) can be present because of connections 
with cranial nerves VIII, IX, and X and the cervical sympathicus [26]. 
5.2.2 Physical examination 
Upon clinical examination, hypo- or dysesthesia in the area of the nervus occipitalis 
major or minor as well as tenderness to pressure over the course of the nervus occipi-
talis major or minor can be observed. A positive Tinel’s sign (pain upon percussion over 
the nerve) can be present. 
 Clinical presentation and a temporary improvement with a local anesthetic diag-
nostic block of the nervus occipitalis major and/or minor confirms the diagnosis [3]. 
False-positive results occur with migraine and cluster headaches [27]. 
5.2.3 Additional tests 
Radiography is recommended to rule out underlying pathologies. Open-mouth X-ray of 
the cervical spine shows possible arthritis of the C2 facet joints. A computer tomogra-
phy scan of the craniocervical junction is indicated in case of suspected neoplastic or 
degenerative osseous pathology. It is important to note that degenerative changes of 
the cervical spinal column do not necessarily correspond with the symptoms the 
patient is presenting. Magnetic resonance imaging is ideal for visualizing disorders of 
the cervical and occipital soft tissues. 
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5.2.4 Differential diagnosis 
Tumors, infection and congenital anomalies (Arnold-Chiari malformation) should be 
ruled out. Occipital neuralgia can be mistaken for migraine, cluster headache, tension 
headache and hemicrania continua. Other structures may cause similar pain such as 
the cervical facet joints (C2-C3), osteoarthritis of the atlanto-occipital of atlanto-axial 
joint, giant-cell arteritis and tumors of the cervical spinal column [28]. 
5.3 Treatment options 
5.3.1 Conservative management  
Conservative treatment focuses on reducing secondary muscle tension and on improv-
ing posture. Pharmacological treatment may include tricyclic antidepressants and 
antiepileptics (carbamazepine, gabapentin and pregabalin). 
5.3.2 Interventional management 
Infiltration of the nervi occipitales with local anesthetic and corticosteroids 
The most common site to infiltrate the nervus occipitalis major is along its course, 
where the nerve penetrates the aponeurosis of the musculus trapezius. Here the nerve 
is most often constricted [29]. Vital et al. found that this site is located on a line that 
connects the middle of the 2 ears, 3.18 cm from the midline [5]. Becser et al. found 
that the subcutaneous path of the nerve starts at the level of the intermastoid line, 1.3 
cm from the midline [30]. Loukas et al. investigated the best site to infiltrate the 
nervus occipitalis major based on external landmarks [31]. On average, the nervus 
occipitalis major is situated 3.8 cm lateral from the midline and one quarter of the 
distance along a line connecting the protuberantia occipitalis externa to the mastoid 
(or 2 cm lateral and 2 cm inferior to the protuberantia occipitalis externa). This is in 
accordance with the findings of Vital [5]. Natsis et al. defined the optimal site for 
infiltration of the nervus occipitalis major 1.5 cm lateral and 2 to 2.5 cm inferior to the 
protuberantia occipitalis externa [32]. Great variability in the course of the nervus 
occipitalis major is described [33]. 
 In a small (n=10) retrospective study by Kuhn et al., the nervus occipitalis major 
was infiltrated with corticosteroids after a positive test block with bupivacaine [26]. 
The authors found pain relief less than 1 week in 10% of patients; 1 week in 30%; 2 
weeks in 30%; 1 month in 10% and more than 2.5 months in 20% of patients. Ham-
mond et al. found a short-term effect (less than 1 week) in 64% of the patients after 1 
infiltration with local anesthetics, 36% of the patients had an effect lasting longer than 
1 month [4]. 
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Botulinum toxin A infiltrations 
Injections with Botulinum toxin type A in 6 patients relieved the sharp, shooting pain 
associated with occipital neuralgia, yet had no effect on the dull, aching pain [34]. 
Quality-of-life measures exhibited some improvement. No significant reduction in pain 
medication was demonstrated. However, in a retrospective case series of 6 patients 
with occipital neuralgia Kapural et al. were able to demonstrate a pain reduction after 
injection of Botulinum toxin A (visual analog scale, VAS, declined from 8±1.8 to 2±2.7) 
as well as an improvement in the pain disability index [35]. The mean duration of pain 
relief averaged 16.3±3.2 weeks. 
Pulsed radiofrequency treatment of the nervi occipitales 
To date 1 case report and 1 prospective trial have been published concerning pulsed 
radiofrequency (PRF) treatment in occipital neuralgia [36,37]. Both used 20-millisecond 
bursts with a frequency of 2 Hz and a maximum temperature of 42°C for 4 minutes to 
the nervi occipitales. In the case report the patient showed 70% pain relief lasting 4 
months. After recurrence of pain, the treatment was repeated with again 70% pain 
relief lasting 5 months. Of the 19 patients included in the prospective trial 68.4%, 
57.9% and 52.6% reported an improvement of 50% or more 1, 2 and 6 months after 
PRF treatment, respectively. The mean VAS score before treatment was 7.5 (standard 
error of the mean, SEM, ±0.4) and declined to 3.5 (SEM±0.8), 3.5 (SEM±0.7), and 3.9 
(SEM±0.8) at 1, 2 and 6 months, respectively (P<0.001, P<0.001, P=0.002, respectively). 
There was a statistically significant improvement in the use of medication and in 
quality-of-life parameters. 
PRF treatment of the C2 ganglion spinale (Dorsal Root Ganglion, DRG) 
A prospective audit looked into the effects of PRF treatment adjacent to the cervical 
ganglion spinale (DRG). In 4 of the 18 patients, the procedure was carried out at C2 
level as a treatment for headache. Two of these 4 patients had a long-term effect (18 
and > 24 months), whereas no improvement was observed in the other 2 patients [38]. 
Subcutaneous neurostimulation of the nervi occipitales 
Weiner and Reed first reported 13 patients who underwent 17 implant procedures for 
medically refractory occipital neuralgia. With follow-up ranging from 18 months to 6 
years, good to excellent results were seen in 12 of 13 patients defined by pain relief 
greater than 50% and requiring little or no pain medications. The thirteenth patient 
was explanted following resolution of the symptoms [39]. 
 Slavin et al. [40] carried out a trial stimulation in 14 patients with therapy resistant 
occipital neuralgia. A definitive neurostimulator was implanted subcutaneously in 10 
patients who had a reduction in pain of greater than 50%. After a mean follow-up of 22 
months, 70% of the patients still had good results. This confirms the results of an 
earlier study by Slavin et al. [41] where 13 of 18 patients experienced >50% pain 
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reduction as a result of test stimulation with a favorable follow-up effect, lasting 28 
months, in 85% of the patients. Other studies also report comparable results [42,43]. 
5.3.3 Complications of interventional management 
Although infection and bleeding are possible complications of any percutaneous 
technique, these have only been reported with subcutaneous lead implantation for 
neurostimulation together with lead migration, hardware erosions, electrode frac-
tures, disconnections, and sepsis [44]. One case report describes sudden unconscious-
ness due to an inadvertent subarachnoidal injection through an os occipitale defect 
after craniotomy [45]. Other possible side-effects of occipital nerve infiltrations include 
temporary dizziness and gait uncertainty, injection site soreness, bradycardia, and 
focal alopecia [46-49]. 
5.3.4 Evidence for interventional management 
Technique  Evaluation 
Single infiltration of the nervi occipitales with local anesthetic and corticosteroids 2 C +  
Pulsed radiofrequency treatment of the nervi occipitales 2 C +  
Pulsed radiofrequency treatment of the cervical ganglion spinale (DRG) 0
Subcutaneous stimulation of the nervi occipitales 2 C + 
Botulinum toxin A injection 2 C ± 
5.4 Recommendations 
A single infiltration of the nervus occipitalis major with local anesthetic and corticoids 
can be considered for the treatment of occipital neuralgia. The effects of Botulinum 
toxin A infiltrations are contradictory. PRF treatment of the nervus occipitalis can be 
considered if infiltration with local anesthetic and corticoids fail to provide sufficient 
pain relief. PRF treatment of the ganglion spinale (DRG) C2 or C3 is only recommended 
in a clinical trial setting. Subcutaneous nerve stimulation can be considered in severe 
disabling pain unresponsive to other treatments. Considering its relatively high cost 
and the invasive nature of the treatment, occipital nerve stimulation should be consid-
ered later in the treatment algorithm and should be performed in experienced centers. 
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5.4.1 Clinical practice algorithm 
 
Figure 1. Treatment algorithm of occipital neuralgia 
 
5.4.2 Techniques 
Infiltration of the nervus occipitalis major and minor 
The infiltration sites of the nervus occipitalis major and minor are determined by 
external landmarks as described by Vital and Becser (see Figure 2) [5,30]. The needle 
(22 gauge) is introduced until there is bone contact or until paresthesia is elicited. 
Subsequently, the needle is slightly withdrawn, and the local anesthetic and cortico-
steroids are injected. 
PRF treatment of the nervus occipitalis major and minor 
The puncture site (22 gauge needle, 5 cm, 1 cm active tip) is located according to the 
external landmarks described by Vital and Becser [5,30]. The thermocouple is intro-
duced after perforation of the skin. The nervus occipitalis major and minor are located 
with a 50 Hz, 0.5 V current until the patient reports paresthesia in the dermatomes of 
the nervus occipitalis major or minor. Subsequently, a PRF treatment (45 V, 20 milli-
seconds, 2 Hz) lasting 120 seconds with a maximum temperature of 42°C is performed 
twice. 
 
Occipital neuralgia 
Positive test block 
Consider infiltration of the 
nervus occipitalis with 
corticosteroids or PRF of the 
nervus occipitalis 
Insufficient effect 
Consider occipital nerve 
stimulation (in experienced 
centers)  
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Figure 2. Landmarks for injection of the nervi occipitales. Illustration: Rogier Trompert, Medical Art. 
Occipital neurostimulation 
The first stage of the procedure (the trial) is performed under mild sedation and local 
anesthesia to monitor the patient’s feedback and ensure the most optimal coverage of 
the painful areas by the stimulation. The patient is placed in a prone position. After 
disinfection and sterile draping, a curved needle is inserted at the upper lateral end of 
the neck and advanced toward the midline of the craniovertebral junction along the 
contour of the C1 arcus vertebralis under fluoroscopic guidance, crossing over the 
anatomic course of the nervus occipitalis major and minor. When positioning of the 
needle is considered satisfactory, a standard 4-contact electrode is advanced through 
the needle, and the tip of the electrode is placed in close proximity of the nervus 
occipitalis major and minor. Correct position of the electrode is verified fluoroscopical-
ly and by intraoperative test stimulation of the awake patient. Once adequate cover-
age has been achieved, the electrode is sutured in place with nonabsorbable sutures 
using 2 plastic anchors provided by the manufacturer to minimize the possibility of 
movement. In case of a successful trial, defined as more than 50% of pain reduction, 
the patient has the second part of the surgical procedure performed under general 
anesthesia. The first incision is made along the retroauricular area in a vertical direc-
tion. The soft tissues are dissected down to the fascia, and a small pocket is created 
O C C I P I T A L  N E U R A L G I A :  E V I D E N C E - B A S E D  M E D I C I N E  
 91
above the fascia. The temporary electrode is removed, and the standard 4-contact 
electrode is then positioned in the same anatomic location. Once the electrode is 
positioned in the right place, the needle is removed and the electrode is anchored to 
the occipital fascia with nonabsorbable sutures using a plastic anchor. Next, a subcuta-
neous pocket is created below the clavicle on the same side to accommodate the 
neurostimulator. Extension cables are advanced through a subcutaneous tunnel, 
establishing a connection between the electrode and neurostimulator. At the end, all 
incisions are closed, cleaned and covered with sterile dressings [40]. 
5.5 Summary 
Occipital neuralgia is responsible for neck pain and headache. No absolute data are 
available about its prevalence and incidence. History, clinical examination, and a 
positive test block with local anesthetic can provide an indication for the diagnosis.  
A single infiltration of the nervus occipitalis major with corticosteroids and local anes-
thetic is advised. If the symptoms are resistant to infiltration with local anesthetic and 
corticosteroids, PRF of the nervus occipitalis can be considered. If pain persists, PRF of 
the ganglion spinale (DRG) C2 or C3 can be considered in a clinical trial setting. Because 
of the cost and invasiveness, subcutaneous nerve stimulation is placed last in the 
treatment algorithm and should only be performed in experienced centers. 
 
This review was initially based on practice guidelines written by Dutch and Flemish 
(Belgian) experts that are assembled in a handbook for the Dutch-speaking pain physi-
cians. After translation, the manuscript was updated and edited in cooperation with 
U.S./International pain specialists. 
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Abstract 
Background and Objectives 
Occipital neuralgia is a paroxysmal non-throbbing, stabbing pain in the area of the 
greater or lesser occipital nerve caused by irritation of these nerves. Although several 
therapies have been reported, no criterion standard has emerged. This study reports 
on the results of a prospective trial with 6 months of follow-up in which pulsed radio-
frequency treatment of the greater and/or lesser occipital nerve was used to treat this 
neuralgia. 
Methods 
Patients presenting with clinical findings suggestive of occipital neuralgia and a positive 
test block of the occipital nerves with 2 ml of local anesthetic underwent a pulsed 
radiofrequency procedure of the culprit nerves. Mean scores for pain, quality of life 
and medication intake were measured 1, 2 and 6 months after the procedure. Pain 
was measured by visual analog and Likert scales, quality of life was measured by a 
modified brief pain questionnaire and medication intake was measured by a medica-
tion quantification scale. 
Results 
During a 29-month period, 19 patients were included in the study. Mean visual analog 
scale and median medication quantification scale scores declined by 3.6 units 
(P=0.002) and 8 units (P=0.006), respectively, after 6 months. Approximately 52.6% of 
patients reported a score of 6 (pain improved substantially) or higher on the Likert 
scale after 6 months. No complications were reported. 
Conclusions 
Pulsed radiofrequency treatment of the greater and/or lesser occipital nerve is a 
promising treatment of occipital neuralgia. This study warrants further placebo-
controlled trials. 
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6.1 Introduction 
The International Headache Society [1] defines occipital neuralgia (ON) as a paroxys-
mal non-throbbing, stabbing pain in the area of the greater or lesser occipital nerve. 
The pain is located in the suboccipital region, radiates over the scalp, and can be 
elicited by applying pressure over the course of the greater or lesser occipital nerve. 
Sometimes, hypoesthesia or dysesthesia is noticed. These findings, in combination 
with a short-term improvement after local anesthetic infiltration, establish the diagno-
sis [1]. In 85% of patients the ON is unilateral. The greater occipital nerve is more 
frequently involved (90%) compared to the lesser nerve (10%) [2]. No data are availa-
ble about the incidence or prevalence. Irritation of the occipital nerves often lies at the 
origin of the neuralgia. Reasons for this irritation are diverse, ranging from vascular 
compression by aberrant vessels [3], giant cell arteritis [4], compression by osteogenic 
tumors [5], arthrosis [6], callus formation after vertebral fractures [7], schwannoma 
[8], C2 myelitis [9] or, as is most often the case, tendinomuscular compression [10]. 
Proposed treatments for ON include local injection therapy [11], subcutaneous electri-
cal stimulation of the occipital nerves [12], acupuncture [13], neurolysis of the occipital 
nerves [14], dorsal root entry zone rhizotomy [15], or even ganglionectomy. However, 
there is no criterion standard for the treatment of ON. Pulsed radiofrequency (PRF) 
therapy is classified as a percutaneous minimal invasive treatment for pain. Descrip-
tions about PRF therapy applied at peripheral nerves for the treatment of neuralgias 
are restricted to case reports precluding any conclusion to its effectiveness [16]. One 
case report is published about PRF therapy for the treatment of ON [17]. To date, no 
long-term prospective trials have been conducted concerning the treatment of ON. We 
present this first prospective clinical trial with 6 months of follow-up in which PRF 
current was used to treat patients with ON. 
6.2 Materials and methods 
6.2.1 Patient selection 
The study was initiated following approval of our ethics committee (Commissie voor 
Medische Ethiek, Ziekenhuis Oost-Limburg, Genk, Belgium). Patients presenting with 
ON (for in- and exclusion criteria see Table 1) were included after obtaining their 
written informed consent. 
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Table 1. In- and exclusion criteria. 
Inclusion Criteria: Exclusion criteria:
Paroxysmal non-throbbing or lancinating pain in the 
area of the greater or lesser occipital nerve  
The pain starts suboccipitally and radiates over 
the vertex 
Hypoesthesia or dysesthesia in the area of the greater 
or lesser occipital nerve 
Pressure over the course of the greater or lesser 
occipital nerve elicits the characteristic pain 
Minimal score of 4 on the visual analog scale (VAS) 
50% or more reduction in the VAS after infiltration 
with local anesthetic 
Polyneuropathies whatever the etiology (diabetic, 
alcoholic, etc) 
Intracranial pathologic lesion 
Central neuropathic pain states 
Psychiatric comorbidity afflicting pain perception 
Previous interventions for treatment of the ON 
Radiofrequency treatment of cervical facet joints 
Cervical epidural injections 
Fibromyalgia and chronic fatigue syndrome 
Neck surgery 
Coagulation disorders 
Infection at the infiltration sites 
Pregnancy 
Cervical spinal cord injury 
Intervertebral disc herniation at level C2-3 
Neoplastic disease causing ON 
 
An infiltration with local anesthetic (bupivacaïne 0.5%, 2ml per nerve) of the culprit 
occipital nerves was performed. Patients with 50% or more pain reduction on the 
visual analog scale (VAS) received a PRF treatment of the same occipital nerves. Cor-
rect injection was confirmed by the presence of scalp anesthesia in the dermatomes 
supplied by the lesser and/or greater occipital nerve. Infiltration sites for the greater 
and lesser occipital nerve were chosen according to the anatomic descriptions by Vital 
et al. [18], Becser et al. [19], Loukas et al. [20] and Natsis et al. [21]. More detailed 
information regarding the infiltration sites is provided in Figure 1. 
 
Figure 1. External anatomical land-
marks for the infiltration of the greater 
and lesser occipital nerve. LON 
indicates lesser occipital nerve; GON, 
greater occipital nerve; GOP, greater 
occipital protuberance; MP, mastoid 
process; X, infiltration site; App, 
approximately. 
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6.2.2 PRF treatment of the occipital nerves 
The target occipital nerves were identified using a 23-gauge CXE-6 needle (Cotop 
International BV, Amsterdam, The Netherlands, 60-mm/5-mm active tip) connected to 
a lesion generator (Cosman RFG-1B generator, Cosman medical Inc. Burlington, MA, 
USA) providing a 50-Hz, 0.5-V current. Correct needle position was confirmed by the 
presence of paresthesia in the concordant dermatomes with sensory thresholds lower 
than 0.5 V. PRF current consisted of 20-msec bursts with a frequency of 2 Hz and 45 V 
and was applied for 240 secs per nerve. Care was taken not to exceed 42° C. No local 
anesthetic was given in order to prevent unintentional anesthesia of the occipital 
nerves. 
6.2.3 Measurements 
The primary outcome measure of the study was the effect of PRF treatment on pain 
measured by a VAS and a 7-point Likert scale [22, 23]. Secondary outcome measures 
were improvement in quality of life and reduction in medication intake assessed by a 
modified brief pain questionnaire and a medication quantification scale (MQS) [24] 
(Grünenthal GmbH, Aachen, Germany), respectively. An example of the Likert scale, 
VAS, and modified brief pain questionnaire is provided below. VAS, modified brief pain 
questionnaire and MQS scores were obtained before infiltration and 1, 2 and 6 months 
after PRF treatment. The Likert scale was acquired 1, 2 and 6 months after PRF treat-
ment. Inquiries about adverse effects were made at every visit. 
6.2.4 Statistical analysis 
StatPlus:mac version 2008 (AnalystSoft, Vancouver, Canada) software was used to 
analyze the data. Mean values of the VAS for pain and the modified brief pain ques-
tionnaire before and after PRF treatment were compared using a paired t-test at an α 
level of 0.05. One-tailed t-test probabilities reported with P values < 0.05 were consid-
ered statistically significant. Data of the MQS before and after PRF treatment were 
compared using a Wilcoxon matched pairs test. Data are presented as mean values ± 
standard error of mean (SEM) for the VAS for pain and the modified brief pain ques-
tionnaire and as median (range) for the MQS. 
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6.3 Results 
In a 29-month period (January 2006 to May 2008) 33 patients suspected with ON 
attended our multidisciplinary pain clinic. Thirteen patients had less than 50% im-
provement after infiltration of the occipital nerves with local anesthetic and were 
excluded from the study. Of the remaining 20 patients, 19 received PRF treatment. 
One patient refused PRF treatment because she was still without pain at the time the 
treatment was scheduled. Demographic data are presented in Table 2. 
 
Table 2. Demographic data of the study population. 
  Number of 
patients 
Percentage Mean age 
(years) 
Range 
(years) 
Gender Female 15 75% 53.3 22-77 
 Male 5 25% 57.6 43-72 
Location Left sided occipital neuralgia GON 0 0%  
  LON 1 5%  
  GON + LON 8 40%  
 Right sided occipital neuralgia GON 0 0%  
  LON 0 0%  
  GON + LON 2 10%  
 Bilateral occipital neuralgia GON 0 0%  
  LON 0 0%  
  GON + LON 9 45%  
Total  20 100%  
GON: greater occipital nerve, LON: lesser occipital nerve
 
Mean VAS scores, mean modified brief pain questionnaire scores and median MQS 
scores of the 19 treated patients are presented in Figure 2. The mean±SEM VAS score 
before treatment was 7.5±0.4 and declined to 3.5±0.8, 3.5±0.7 and 3.9±0.8 at 1, 2 and 
6 months, respectively (P<0.001, P<0.001, and P=0.002, respectively). The median 
MQS score before treatment was 11.2 (range 18.2) and declined to 4.4 (range 18.2), 
3.4 (range 17.1) and 2.2 (range 17.1) at 1, 2, and 6 months, respectively (P<0.01, 
P=0.011, and P=0.006, respectively). 
 The results for the quality of life parameters (disturbance of daily activity, mood 
disturbance, and sleep disturbance) are presented in Table 3. Of the 19 patients 13 
(68.4%), 11 (57.9%), and 10 (52.6%) mentioned a score of 6 or more on the Likert scale 
1, 2, and 6 months after PRF treatment, respectively. No adverse effects were report-
ed. The VAS score of the patient who refused PRF treatment was 6 at baseline and 0, 2, 
and 7 at 1, 2, and 6 months after infiltration with local anesthetic, respectively. 
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                 VAS          Daily activity        Mood               Sleep                 MQS 
 
Figure 2. Mean scores for the visual analogue scale (VAS), disturbance of daily activity-mood-sleep and 
median score for the medication quantification scale at 1, 2, and 6 months after therapy. * P<0.05. 
 
Table 3. Evolution of quality of life parameters 1, 2, and 6 months after treatment 
 Baseline 1 mo 2 mo 6mo 
Disturbance of daily activity 6±0.6 3.2±0.8 (P=0.035) 3.2±0.8 (P=0.004) 3±0.8 (P=0.002) 
Mood disturbance 4.8±0.8 3±0.8 (P=0.06) 2.6±0.8 (P=0.025) 2.7±0.8 (P=0.037) 
Sleep disturbance 6.6±0.8 3.6±0.9 (P=0.009) 3.5±0.9 (P=0.009) 3.6±1 (P=0.01) 
Values are mean±SEM. 
6.4 Discussion 
This first prospective study on PRF for the treatment of ON shows a significant pain 
relief and reduced pain medication intake for 6 months. Sleep, mood and daily activity 
also improved during the 6 months of follow-up. 
 Kuhn et al. [25] prospectively identified 12 patients in the emergency department 
who met the International Headache Society criteria for ON. Following a positive test 
block (1-3ml of bupivacaine 0.5% with epinephrine), the patients received an infiltra-
tion with corticosteroids. In 70% of patients the pain recurred within 2 weeks. Pro-
longed pain relief for more than 2 months was observed in 20% of the cases. Compa-
rable outcomes were found in a study performed by Hammond and Danta [2]. In our 
experiment only 1 patient (5%) had pain relief for more than 2 months after a single 
injection with local anesthetic. Mechanisms responsible for long-term pain relief after 
a single dose of local anesthetic still need to be elucidated. Injections with Botulinum 
toxin type A [26] in 6 patients relieved the sharp, shooting pain associated with ON, yet 
had no effect on the dull, aching pain. Quality of life measures exhibited some im-
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provement. No significant reduction in pain medication was demonstrated. However, 
in a retrospective case series of 6 patients with occipital neuralgia Kapural et al. [11] 
were able to demonstrate a pain reduction after injection of Botulinum toxin A (VAS 
declined from 8±1.8 to 2±2.7) with a mean duration of 16.3±3.2 weeks. After implanta-
tion of a subcutaneous electrode at the level of C1 [27], 7 of 14 (50%) ON patients had 
significant to complete pain reduction. Of 10 patients, 3 had their neurostimulator 
removed (1 owing to infection, 1 owing to lead migration and spasm of the neck, 1 
owing to spontaneous improvement of pain). In a case series of 6 patients with ON 
who underwent occipital nerve electrical stimulation, a reduction in VAS scores for 
pain (8.66±1.0 to 2.5±1.3) and pain disability index were noted after 3 months follow-
up [12]. After performing intradural dorsal rhizotomies of C1 to C4 in 9 patients, 
Horowitz and Yonas [28] found prolonged complete relief in 44% of patients. Two 
patients (22%) had complications (wound infection, muscular neck pain resulting in 
reduced range of motion). 
 Compared with the aforementioned results of other treatment modalities, PRF 
treatment for ON shows a higher efficacy without any complications. Nevertheless, it 
should be mentioned that in 2 studies [27, 28] the follow-up was longer than in our 
study. No adverse effects were reported by the patients in our study. 
 Several limitations in our study are worth mentioning. First, although the VAS, 
Likert scale and modified brief pain questionnaires are validated tools in the quantifi-
cation of pain, they are subjective outcome measures because they are dependent on 
personal interpretation and variations. With the use of the MQS, we tried to circum-
vent part of this subjective interpretation. Second, the small sample size limits the 
power of the outcomes. Finally, it is worth mentioning that uncontrolled trials have a 
tendency to overestimate treatment effects. 
 In conclusion, PRF for the treatment of ON shows promising results that need to 
be confirmed by larger placebo-controlled studies. 
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Abstract 
Background 
At present, development of biomarkers to detect the intensity or duration of pain has 
been unsuccessful. Instead, biomarkers to distinguish different types of pain are well 
within reach. Despite numerous immunological and neurochemical pathways involved 
in the generation of neuropathic pain have been discovered through animal research, 
physicians still rely on questionnaires to detect neuropathic pain in man. 
Methods 
We determined serum, plasma and CSF concentrations of TNF-α, BDNF, CGRP-α, NPY 
and GABA in patients with failed back surgery syndrome and neuropathic pain (NP-
group) before and 4 weeks after spinal cord stimulation (SCS), and compared these 
values to serum and plasma concentrations of pain-free controls (PF-controls) and CSF 
concentrations of controls with nociceptive pain (NC-controls). 
Results 
BDNF and CGRP-α serum concentrations in the NP-group were markedly lower than in 
the PF-group (P≤0.01 and P≤0.0001, respectively) and rose after SCS (P≤0.05 in both 
cases), whereas initial serum and plasma concentrations of TNF-α (P≤0.001 and 
P≤0.002, respectively) and NPY (P≤0.02 and P≤0.001, respectively) and plasma concen-
trations of GABA (P≤0.005) were higher in the NP-group but unchanged after SCS. TNF-
α was the only biomarker in CSF that was higher in the NP-group compared to the NC-
group. 
Conclusions 
We present a series of changes in biomarker concentrations in blood and CSF that 
favor inflammation and jeopardize neuroprotection in failed back surgery syndrome 
and can be used as a biomarker set to distinguish neuropathic pain from other types of 
pain. 
B I O L O G I C A L  I N D I C A T O R S  F O R  N E U R O P A T H I C  P A I N  
 109
7.1 Introduction 
The concept of biomarkers for pain is controversial because the expression of pain not 
only represents a nociceptive mechanism but also the processing of this nociceptive 
information at different spinal and supraspinal levels, not in the least by emotions and 
affective state. As such, a biomarker for pain itself can only be a surrogate for the 
mechanisms mentioned above. This said, biomarkers for the detection of the intensity 
or duration of pain seem unfeasible at present [1]. Instead, biomarkers to distinguish 
different types of pain are well within reach because recent investigations uncovered 
biomarkers that allowed for differentiation between primary headache disorders [2]. 
Along these lines, animal research has revealed a host of immunological and neuro-
chemical pathways that are potentially involved in the initiation and maintenance of 
neuropathic pain (NP) [3-6]. To date, no application exists for these substances as 
biomarkers to distinguish NP from other types of pain in humans, and physicians still 
rely on clinical examination and questionnaires as screening tools to detect NP [7-9]. 
Clinical practice would strongly benefit from diagnostic tests based on the measure-
ment of factors in blood and/or cerebrospinal fluid (CSF), because they would supple-
ment the current subjective assessment of NP and improve research and treatment of 
this condition. 
 Among the various types of NP in humans, neuropathic low back and radicular 
pain are the most prevalent [10-12]. Failed back surgery syndrome (FBSS) constitutes a 
major source of this neuropathic low back and radicular pain. With a prevalence of 
0.6% [13] and reports of up to 50% of lumbar surgeries resulting in FBSS [14], the 
disorder forms a heavy burden for patients and society. Drugs effective in diabetic 
polyneuropathy and postherpetic neuralgia fail to demonstrate superiority over place-
bo in radicular NP [15-17]. However, in a recent prospective randomized controlled 
multicenter trial, spinal cord stimulation (SCS) was superior to conventional medical 
management in successfully treating patients with FBSS [18]. Nevertheless, the exact 
mechanism of action by which SCS acts on NP is largely unknown. 
 In the present study we measured CSF and blood concentrations of a series of 
molecules involved in the pathophysiological processes of NP and investigated their 
possible usefulness as biomarker to distinguish NP from nociceptive pain in humans. 
Since in recent years the neuroinflammatory cascade, peptides of the calcitonin family, 
neurotrophins, and excitatory as well as inhibitory neurotransmitters have been 
implicated in the pathophysiology of NP [3, 4, 6, 19, 20], we focused on one well-
established representative of each of these categories: tumor necrosis factor-α (TNF-
α), calcitonin gene-related peptide-α (CGRP-α), brain-derived neurotrophic factor 
(BDNF), neuropeptide Y (NPY) and γ-aminobutyric acid (GABA). Their concentrations in 
blood and CSF of patients with NP have been compared with those in CSF of patients 
suffering from nociceptive pain and with those in the blood of pain-free controls. 
Furthermore, the effect(s) of SCS on these factors was studied by assessing their 
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concentrations in blood and CSF in patients with FBSS and NP, before and after 4 
weeks of SCS. 
7.2 Materials and methods 
7.2.1 Study set-up 
This single center study was approved by the Ethics Committee of our hospital (Com-
missie voor Medische Ethiek, Ziekenhuis Oost-Limburg, Genk, Belgium). Patients were 
recruited from our patient directory and from referrals to our tertiary pain clinic. 
Researchers obtaining patient questionnaires and performing serum, plasma and CSF 
analyses were unaware of the group the patient was allocated to. The timeline of the 
study is presented in Figure 1. 
 
Figure 1. Timeline of the study. 
Before (pre-) and after (post-) 4 weeks of spinal cord stimulation (SCS) cerebrospinal fluid (CSF), serum and
plasma samples were taken from patients with neuropathic pain (NP). The pre-SCS serum and plasma 
samples were compared with age- and gender-matched controls with nociceptive pain (NC-controls) 
regarding CSF and pain-free controls (PF-controls) regarding serum and plasma. Post-SCS samples were 
compared with the pre-SCS samples. 
 
In short, patients (NP-group) eligible for inclusion in the study underwent CSF, plasma 
and serum sampling before epidural lead insertion (pre-SCS). Next, an epidural lead 
was inserted and patients received SCS for 4 weeks. Thereafter, post-SCS samples from 
CSF, serum and plasma were taken again in the NP-group. The pre-SCS samples of the 
NP-group were compared to CSF samples of age- and gender-matched patients with 
nociceptive pain (NC-controls) and to serum and plasma samples of age- and gender-
matched pain-free volunteers (PF-controls). Furthermore, the post-SCS samples of the 
NP-group were compared with the pre-SCS samples. 
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7.2.2 Patient population 
Patients and controls were included after their written informed consent. Patients with 
NP (NP-group) suffered from FBSS and presented with predominant lumbosacral 
radicular pain, which was confirmed by a diagnostic nerve root block. Patients with 
nociceptive pain (NC-controls) were selected from patients undergoing lower limb 
surgery (total knee replacement, diagnostic knee arthroscopy) under spinal anesthesia. 
Pain-free controls (PF-controls) were healthy volunteers. NC- and PF-controls were 
age- and gender-matched to the NP-group. Before sample collection, NP-patients and 
NC-controls rated their pain score using a visual analogue scale (VAS) [21]. A validated 
Dutch DN4 questionnaire [22] was used to confirm the neuropathic nature of the pain 
(cut-off ≥ 4/10) in the NP-group and the non-neuropathic nature of the pain in the NC-
controls (<4/10). Patients with conditions known to alter CSF, serum or plasma levels 
of the investigational substances were excluded from the study. In- and exclusion 
criteria are presented in Table 1. Depression and anxiety disorders were ruled out by 
the Montgomery-Asberg Depression Rating Scale (MADRS) from which the 4 somatic 
items were excluded to minimize the effect of the physical items when examining 
affective state (cut-off > 7) [23], and by psychiatric evaluation. Infection and coagula-
tion disorders were ruled out by blood examination. Other exclusion criteria were 
eliminated by history taking and clinical examination. 
 
Table 1. In- and exclusion criteria. 
Inclusion criteria Exclusion criteria
Neuropathic pain group: Multiple sclerosis
Failed back surgery syndrome Lupus erythematosus
Predominant radicular leg pain Post-traumatic stress disorder
DN4 score ≥ 4 Depression
 Parkinson’s disease
Nociceptive pain group Acquired immunodeficiency syndrome
Pain in the leg requiring: Stroke
   - Total hip replacement Head trauma or spinal cord damage
   - Total knee replacement Normal pressure hydrocephalus
   - Diagnostic knee arthroscopy Fibromyalgia or chronic fatigue syndrome
DN4 score < 4 Infections either locally or systemic
 Polyneuropathy (diabetic, alcoholic, drug-induced)
 Pregnancy
 Previous or current malignancies
 Inability to give informed consent
 Coagulation disorders
 Primary headache disorders
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7.2.3 Cerebrospinal fluid sampling 
All CSF samples were collected between 8 AM and 12 AM, to minimize possible effects 
of circadian rhythms. Lumbar puncture was performed at the L3-4, L4-5 or L5-S1 
interspace depending on the location of previous lumbar surgery in the NP-group or 
the surgery the patient had to undergo in case of the NC-controls. Lumbar punctures 
were carried out by board-certified anesthesiologists and pain physicians familiar with 
the procedure. In short, the lumbar skin was disinfected with Hibitane Plus (chlorhexi-
din 0.5% in isopropanol 70%, Mölnlycke Health Care, Gothenburg, Sweden) and draped 
sterile. After local skin anesthetic (2 ml Linisol 2%, lidocaine 2%, Braun, Melsungen, 
Germany), a 120 mm 27G pencil point spinal needle (Braun, Melsungen, Germany) was 
introduced into the subdural space and 2 ml CSF was collected (2.5 ml syringe BD 
plastipak, Madrid, Spain). When the CSF was not visually clear, the patient was exclud-
ed from the study. CSF samples were stored at – 72° C until analysis. 
7.2.4 Serum and plasma sampling 
Blood samples were collected from a forearm vein between 8 AM and 12 AM to 
minimize possible effects of circadian rhythms (lithium-heparin tubes for plasma 
samples, silicone-silica SST II Advance tubes for serum samples and EDTA tubes for 
blood platelet count; Vacutainer, BD, Plymouth, United Kingdom). Serum samples 
were left to clot for 15 min to ensure platelet degranulation. Serum and plasma were 
obtained by centrifugation for 10 min at 4.500 rpm at room temperature (Eppendorf 
Centrifuge 5702R, Eppendorf, Hamburg, Germany). Supernatants were aliquoted and 
stored at -72°C until analysis. Blood platelet counts were determined by flowcytometry. 
7.2.5 Measurements of BDNF, TNF-α, NPY, GABA and CGRP-α 
CSF, serum and plasma concentrations were determined by commercially available 
high sensitivity enzyme-linked immunosorbent assays (ELISA) for BDNF (R&D systems 
Europe, Abingdon, United Kingdom; detection range, DR, was 20-4,000 pg/ml), TNF-α 
(Abazyme, Needham, USA; DR: 2.4-500 pg/ml), NPY (Peninsula Laboratories, Bachem, 
United Kingdom; DR: 10–39 pg/ml), CGRP-α (Nuclilab, Ede, The Netherlands; DR: 2.15-
300 pg/ml) and GABA (ImmunDiagnostik AG, Bensheim, Germany; DR: 0.05-2 μmol/l) 
using the procedure recommended by the manufacturers. 
7.2.6 Epidural lead implantation and spinal cord stimulation 
Patients received epidural lead implantation under local anesthesia with light sedation 
(diazepam 5mg intravenously; Roche, Brussels, Belgium) and prophylactic antibiotics 
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(cefazoline 2g; Sandoz, Kundl, Austria). The lumbar skin was disinfected with Hibitane 
Plus (0.5% chlorhexidin in 70% isopropanol, Mölnlycke Health Care) and draped sterile. 
After local skin anesthetic with lidocaine (Xylocaine 2% with epinephrine 1:80.000, 
AstraZeneca, Amsterdam, The Netherlands) a Tuohy-needle was inserted into the T12-
L1 epidural space via a paramedial approach and a percutaneous quadripolar epidural 
lead (Pisces quad compact model; Medtronic, Minneapolis, MN, USA) or a percutane-
ous octapolar epidural lead (Octad standard model; Medtronic) was advanced until full 
coverage of the painful dermatomes with paresthesia was attained. Next, the epidural 
lead was tunneled subcutaneously towards the lateral side and connected to an 
external trialing neurostimulator (Medtronic) for 4 weeks. Spinal cord stimulation 
parameters of the NP-group are presented in Table 2. 
 
Table 2. Spinal cord stimulation parameters of patients in the neuropathic pain group. Data concerning 
voltage, pulse width and frequency are missing for patient 19. D indicates dorsal vertebra level. 
Patient Voltage 
(V) 
Pulse width
(msec) 
Frequency 
(Hz) 
quadri-/octapolar
 lead 
position of the tip of 
the electrode  
1 2.7 330 60 8 D7 
2 3.4 330 60 4 D8 
3 7.5 330 70 4 D9 
4 5 420 60 4 D9 
5 7.2 420 60 4 D9 
6 1.7 330 60 8 D8 
7 3.2 420 60 4 D9 
8 2.5 450 60 4 D8 
9 8 420 60 4 D9 
10 3.7 330 40 8 D7 
11 6 330 60 4 D8 
12 4.5 420 60 4 D9 
13 5.2 420 40 4 D10 
14 5 420 60 4 D10 
15 4 330 60 4 D9 
16 5.5 450 60 4 D9 
17 3 420 60 4 D10 
18 2.4 360 60 4 D8 
19 - - - 4 D11 
20 4 300 60 4 D8 
7.2.7 Statistical analyses 
Statistical analyses were carried out using Prism 5.0d (GraphPad Software, San Diego, 
CA, USA). Because data were not normally distributed (Shapiro-Wilk normality test), 
non-parametric tests were used for analysis. A Mann Whithey-U test and Wilcoxon 
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matched-pairs signed rank test (confidence intervals 95%) were used to compare non-
matched and age- and gender-matched data between groups, respectively. Spear-
man’s correlation test (confidence interval 95%) was performed to investigate a 
possible correlation between serum, plasma, and CSF-concentrations. Data are pre-
sented as means ± SEM. α=5%. 
7.3 Results 
7.3.1 Patient and control characteristics 
Over a period of 36 months (February 2009 - February 2012) 26 patients were 
screened for inclusion in the NP-group. Six patients were excluded due to a MADRS 
score >7. Of the remaining 20 patients, 12 were matched to NC-controls and 13 to PF-
controls. The demographic data of the different groups are presented in Table 3. 
 
Table 3. Patient and control demographics. 
 Total NP-group (n=20) NP-group matched
to NC-controls 
Matched NC-controls 
(n=12) 
  
Male/female (%) 45/55 60/40 60/40 
Age (years) 52±3 56±5 56±5 
Etiology of pain  L4 radicular pain: 5% L4 radicular pain: 8.3% Meniscal tear:  70% 
 L5 radicular pain: 35% L5 radicular pain: 25% Gonarthrosis 30% 
 S1 radicular pain: 35% S1 radicular pain: 41.7%  
 L5 & S1 radicular pain: 
25% 
L5 & S1 radicular pain: 
25% 
 
VAS 85±2 78±5 77±6 
Duration of pain (months) 48±6 45±8 33±14 
Time (months) between diagnostic nerve root
block and CSF collection 
18±5  
Time (months) between surgery and sample 
collection 
57±8  
 NP-group matched 
to PF-controls 
Matched PF-controls 
(n=13) 
Male/female (%) 44.5/55.5 44.5/55.5 
Age (years) 47±3 47±3 
Etiology of pain  L4 radicular pain: 0% - 
 L5 radicular pain: 38.5% - 
 S1 radicular pain: 38.5% - 
 L5 & S1 radicular pain: 
23% 
- 
VAS 85±2 - 
Duration of pain (months) 53±8 - 
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L5 and S1 radicular pain was the most common etiology of pain in the NP-group, 
whereas in the NC-group this was a meniscal tear. There were no differences in the 
duration of pain nor in VAS-scores between the age- and gender-matched NP-group 
and NC-controls (45±8 months vs. 33±14 months, and 78±5 vs. 77±6, respectively). In 
the NP-group, the time between surgery and sampling of blood and of CSF for the 
study was 57±8 months and the time between diagnostic nerve root block and sam-
pling of blood and of CSF for the study was 18±5 months. 
7.3.2 Serum, plasma and CSF concentrations of BDNF, TNF-α, CGRP-α, NPY and 
GABA in patients with NP and in controls 
BDNF 
The data are presented in Figure 2a. Whereas in plasma there was only a trend to-
wards a lower BDNF-concentration in the NP-group compared with PF-controls 
(1.26±0.28 ng/ml vs. 1.63±0.11 ng/ml, P=0.06, respectively), in serum of the NP-group 
the BDNF-concentration was clearly lower than in the PF-controls (6.16±2.07 ng/ml vs. 
16.85±2.26 ng/ml, P≤0.01, respectively). In the NP-group and PF-group there was an 
increase in serum BDNF-concentration compared with plasma (P≤0.0005 and P≤0.001, 
respectively). No difference was seen in the number of platelets between the NP-
group and PF-controls (258.6±25.5*1000 platelets/μl vs. 237.0±8.2*1000 platelets/μl) 
but the calculated amount of BDNF released per platelet (serum BDNF concentration 
minus plasma BDNF concentration/number of platelets [24]) was lower in the NP-
group than in the PF-controls (22.8±11.7 ag/platelet vs. 61.6±8.4 ag/platelet, P≤0.02, 
respectively). In CSF of the NP-group and NC-controls, BDNF concentrations were 
below the detection limit (20 pg/ml) of the ELISA. 
TNF-α 
The data are presented in Figure 2b. TNF-α concentrations were higher in serum 
(100.4±86.3 pg/ml vs. 1.5±0.2 pg/ml, P≤0.001), plasma (120.2±103.2 pg/ml vs. 2.0±0.6 
pg/ml, P≤0.002) and CSF (15.4±2.1 pg/ml vs. 11.0±1.0 pg/ml, P≤0.02) of NP-patients 
than of PF- and NC-controls, respectively. In the NP-group, serum and plasma concen-
trations of TNF-α did not differ from each other. In the NP-group, a positive correlation 
existed between serum and plasma concentrations of TNF-α on one hand and CSF 
concentrations of TNF-α on the other (r=0.86, P≤0.0001 and r=0.77, P≤0.0001, respec-
tively). 
CGRP-α 
The data are presented in Figure 2c. CGRP-α concentrations in plasma and serum of 
the NP-group were lower than of PF-controls (13.5±4.2 pg/ml vs. 19.8±1.7 pg/ml, 
P≤0.02, and 12.4±2.1 pg/ml vs. 62.0±8.0 pg/ml, P≤0.0001, respectively). CGRP-α 
concentrations were markedly higher in serum than in plasma in the PF-controls 
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(P≤0.001) but not in the NP-group indicating decreased release of CGRP-α from blood 
platelets in the NP-group. No differences were noted in CSF concentration of CGRP-α 
between the NP-patients and CSF-controls (6.2±2.0 pg/ml vs. 5.0±1.1 pg/ml). However, 
in the NP-group we found a positive correlation between CSF and serum concentra-
tions of CGRP-α (r=0.69, P≤0.005). 
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Figure 2. Serum, plasma and CSF concentrations of BDNF (a), TNF-α (b), CGRP-α (c) NPY (d) and GABA (e) in 
NP patients compared to controls and the effect of SCS on BDNF (f), TNF-α (g), CGRP-α (h), NPY (i) and GABA 
(j), concentrations in serum, plasma and CSF of NP patients. Capped lines delineate compared groups. * 
P≤0.05, ** P≤0.01, *** P≤0.001. 
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NPY 
The data are presented in Figure 2d. NPY-concentrations in plasma and serum of the 
NP-group were higher than in PF-controls (519.2±75.6 pg/ml vs. 289.2±21.0 pg/ml, 
P≤0.001 and 739.9±156.6 pg/ml vs. 397.7±18.0 pg/ml, P≤0.02, respectively). The NPY 
concentration in serum was markedly higher than in plasma, in both the NP-group and 
the PF-controls (P≤0.005 and P≤0.001, respectively) indicating substantial release of 
NPY from blood platelets. The calculated concentration of NPY in blood platelets of the 
NP-group was not different from that in PF-controls (781.6±409.7 zg/platelet vs. 
468.4±69.37 zg/platelet). NPY-concentrations in CSF showed no difference between 
the NP-group and NC-controls (190.7±35.3 pg/ml vs. 270.6±123.0 pg/ml). In the NP-
group, this concentration revealed positive correlations with the NPY-concentration in 
serum and plasma (r=0.48, P≤0.02 and r=0.77, P≤0.0001, respectively). 
GABA 
The data are presented in Figure 2e. Patients in the NP-group exhibited a higher 
plasma concentration of GABA than PF-controls (150.3±47.2 nmol/l vs. 70.1±7.7 
nmol/l, P≤0.005) but no difference was observed between in GABA serum concentra-
tion (303.7±244.1 vs. 62.4±4.4 nmol/l). In the NP-group, the serum concentration of 
GABA was markedly higher than the plasma GABA concentration (227.9±149.8 nmol/l 
vs. 172.1±45.2, P≤0.01), whereas for the PF-controls only a trend for such a difference 
was seen (70.1±7.7 nmol/l vs. 62.4±4.4 nmol/l, P=0.06) suggesting release of GABA 
from blood platelets in patients with NP. We found no correlation between plasma and 
serum concentration of GABA on the one hand and CSF GABA concentration on the 
other. There was no difference in the GABA CSF concentration of NP-patients and NC-
controls (644.3±358.1 nmol/l vs. 1040.0±315.4 nmol/l). 
7.3.3 Effect of spinal cord stimulation on BDNF, TNF-α, CGRP-α, NPY and GABA 
concentrations in serum, plasma and CSF of NP patients 
Four weeks treatment with SCS resulted in a clear reduction of VAS pain scores 
(85.6±2.3 vs. 37.8±5.4, P≤0.0005) in the NP-group, which was accompanied by a 
marked increase in serum and plasma BDNF concentrations (4.5±1.4 ng/ml vs. 9.6±2.6 
ng/ml, P≤0.05 and 1.2±0.2 ng/ml vs. 1.9±0.4 ng/ml, P≤0.01, respectively; Figure 2f) and 
serum CGRP-α concentration (12.3±1.5 vs. 21.8±6.3 pg/ml, P≤0.05; Figure 2h). 
 However, serum and plasma concentrations of NPY, TNF-α and GABA showed no 
changes after 4 weeks treatment with SCS nor did the CSF concentration of any of the 
test substances (Table 4). 
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Table 4. Serum, plasma and CSF concentrations of tumor necrosis factor-α  (TNF-α), calcitonin gene-related 
peptide-α  (CGRP-α), neuropeptide Y (NPY) and γ-aminobutyric acid (GABA) in the NP-group before (Pre-SCS) 
and 4 weeks after spinal cord stimulation (Post-SCS). 
 Serum  Plasma  
 BS Post-SCS P-value BS Post-SCS P-value 
NPY (pg/ml) 799.7±129.9  697.5±121.5 0.36 589.5±80.2 556.3±86.0  0.40 
TNF-α (pg/ml) 129.9±81.1  159.9±100.8 0.41 133.3±82.2 153.0±94.32  0.31  
GABA (nmol/l) 227.9±149.8  239.4±131.8 0.24 172.1±45.2 178.4±87.8  0.32  
 CSF   
 BS Post-SCS P-value  
CGRP-α (pg/ml)  7.1±1.6  6.5±2.0 0.33  
NPY (pg/ml) 303.6±88.3  176.7±38.6 0.50  
TNF-α (pg/ml) 14.8±1.9  17.6±2.4 0.37  
GABA (nmol/l) 668.4±252.3  497.1±161.7 0.50  
 
7.3.4 Correlation of age, pain intensity and duration of pain with BDNF, TNF-α, 
CGRP-α and NPY concentrations 
In the NP-group, we found no correlation between serum, plasma and CSF concentra-
tions of BDNF, NPY, CGRP-α and TNF-α on the one hand and age, VAS-scores and 
duration of pain on the other. 
7.4 Discussion 
In the present study we investigated the usefulness of different substances to distin-
guish NP from other types of pain. The results show that patients with NP exhibit 
decreased serum concentrations of BDNF and CGRP-α and increased serum and plas-
ma concentrations of TNF-α and NPY and increased plasma concentrations of GABA 
when compared to pain-free controls. Moreover, the CSF concentration of TNF-α was 
higher in patients suffering from NP than in patients with nociceptive pain. Four weeks 
treatment with SCS resulted in marked increases in serum and plasma BDNF concen-
trations and serum CGRP-α concentration. 
 To our knowledge, this is the first report about BDNF serum concentrations in 
humans with NP. Our observations are similar to the ones seen in neurodegenerative 
disorders such as multiple sclerosis, white matter atrophy, cognitive deficits and 
Alzheimer’s disease [25-28], where pre-treatment BDNF concentrations are low and 
successful therapy restores BDNF levels [29]. Given the facts that 1) there is a bidirec-
tional high-capacity saturable transport system for BDNF between the CNS and blood 
[30], 2) blood concentrations of BDNF reflect CNS levels across species [31] and 3) 
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BDNF promotes neuronal survival and proliferation [32], low serum BDNF concentra-
tions may indicate a state of insufficient neuroprotection against nerve injury eventu-
ally leading to NP. Therefore, our data suggest that NP should be considered as a 
neurodegenerative disease. To find the origin of low serum BDNF concentrations in 
patients with NP, we determined the number of platelets in NP patients because 
platelets contain large stores of BDNF [33], but found no difference with PF-controls. 
However, when we calculated the amount of BDNF released per platelet it appeared 
that platelets collected from NP patients released 2.7-fold less BDNF than PF-controls. 
This finding indicates that NP patients either have an impaired release of BDNF from 
platelets and/or have depleted platelet BDNF-stores. Another possible cause of the 
lowered serum BDNF concentrations is the elevated TNF-α concentration in our NP-
group because negative correlations between serum TNF-α and BDNF levels have been 
uncovered earlier [34]. Four weeks treatment with SCS resulted in a marked reduction 
of pain scores and in a marked increase in BDNF serum and plasma concentrations. It is 
unlikely that the increase in BDNF concentration results from the surgery to implant 
the SCS hardware because Chimienti et al. [35] showed a decrease in serum BDNF 
concentration after major abdominal surgery, which after 5 days subsequently re-
turned to pre-surgery levels. Therefore, BDNF is a good candidate to be used as a 
biomarker to detect NP in FBSS and to monitor the effect of SCS treatment. 
 The elevated TNF-α concentrations in our NP patients are in contrast with earlier 
studies on complex regional pain syndrome and subacute sciatica, conditions associat-
ed with NP, that showed that in the CSF of patients levels of interleukin (IL)-1β, IL-6 
and IL-8 were elevated but TNF-α had remained unaffected [36, 37]. However, in the 
study of Brisby and colleagues, patient selection was not made on the basis of neuro-
pathic pain but by IASP-criteria for complex regional pain syndrome (CRPS) and clinical 
findings of sciatica and vertebral disc herniation [37]. Therefore, the biomarker profile 
these authors proposed could be specific for CRPS or subacute sciatica. Our findings 
are in line with results from research in patients with painful neuropathies showing 
elevated serum TNF-α concentrations in contrast with patients with painless neuropa-
thies [38]. Also, in animal research using whole blood transcriptosomes the TNF-
receptor superfamily gene was identified and validated as a biomarker for mechanical 
allodynia in a chronic constriction injury rat model [39]. Consequently, we suggest that 
TNF-α could be a possible biomarker for NP in FBSS. 
 CGRP-α concentration was decreased in our NP-group compared to PF-controls. 
Moreover, in the NP-group CGRP-α release from platelets was lower, closely resem-
bling our observations concerning BDNF. These results indicate that storage and 
release of neurotrophins and neuropeptides from platelets may play a more important 
role in NP than currently supposed. A recent animal study [40] showed that CGRP-α 
has potent anti-inflammatory properties in vivo, mainly through inhibition of TNF-α 
release from macrophages and induction of IL-6 and IL-10. This means that the de-
creased plasma and serum levels of CGRP-α in our NP-group could be responsible for 
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the observed increases in TNF-α concentrations. Indeed, in patients afflicted by chronic 
CRPS, a condition associated with NP and pronounced local and systemic inflamma-
tion, the CGRP-α concentration was also lower than in controls [41]. However, the 
latter results were not replicated in a study on acute CRPS [42], suggesting a time-
dependent factor in expression of biomarkers. The underlying mechanisms of lowered 
plasma and serum CGRP-α in patients suffering from NP were not investigated in our 
study and need further elucidation. Four weeks treatment with SCS also resulted in a 
marked increase in CGRP-α serum concentrations. Whereas this concentration can 
increase after soft tissue injury or hip fracture [43, 44] it seems unlikely such a rise 
would persist for 4 weeks after the precipitating incident. Moreover, the amount of 
tissue damage caused by implantation of a DCS system is minimal. Consequently, in 
addition to BDNF, CGRP-α seems to qualify for a biomarker to detect NP in patients 
with FBSS. 
 Our data reveal that NPY concentrations in plasma and serum of NP patients are 
higher than in PF-controls. Despite the fact that NPY is thought to be anti-nociceptive 
and neuroprotective [45], apparently, in our study these higher concentrations did not 
prevent the occurrence of NP. Our results are in line with two other studies, one in 
patients with sciatica [46] and another in patients with fibromyalgia [47], which failed 
to show a correlation between plasma NPY concentration and pain scores. In contrast, 
NPY concentrations are lowered in the affected limb of patients with CRPS. However, 
this could represent a reduction in sympathetic activity rather than a nociceptive effect 
because no comparison was made with a control group [48]. 
 Although blood concentrations and platelet uptake of GABA have been extensively 
investigated in psychiatric disorders and epilepsy [49, 50] and GABA-ergic pathways 
play an important role in the development of NP [51], elevated plasma levels of GABA 
in NP patients are a new finding. Yet, previous data suggested that platelets can 
function as a peripheral model to study neuronal GABA-ergic functions [52, 53]. In 
animal research, results on the expression of GABA are highly dependent on the 
animal model used to induce NP and on the time point at which GABA concentrations 
are measured. However, a common denominator in animal models is the increased 
intracellular and decreased extracellular spinal concentration of GABA during the late 
phase of NP [19, 54]. Our results in humans show a trend towards a lower GABA 
concentration in the CSF of patients with NP, hence corroborating the results from 
animal research and implicating GABA-ergic pathways in the development of NP in 
humans with FBSS. However, the increase in extracellular GABA level as seen during 
SCS in animals could not be replicated in patients. 
 In our study, blood concentrations of TNF-α, NPY and CGRP-α correlated with CSF 
concentrations in NP patients. These findings are in line with animal studies demon-
strating that the blood-spinal cord barrier (BSCB) after peripheral nerve injury becomes 
permeable to substances with a molecular weight up to 400 kDa [55]. This disruption 
of the BSCB may be triggered by pro-inflammatory mediators and gives rise to passive 
C H A P T E R  7  
 122 
influx of circulating cytokines and penetration of immune cells in the spinal cord. 
Similar findings were made in humans suffering from sciatica caused by disc herniation 
[56]. The fact that in CSF of NP patients only the TNF-α concentration markedly dif-
fered from that in NC-controls can be explained by the low concentration of these 
molecules in the CSF and, furthermore, from possible (small) differences between 
patients and controls on one hand and our small sample size on the other, which may 
have obscured the presence of small inter-individual differences. 
 We could not find a correlation between pain intensity or pain duration and the 
concentrations of the substances tested, indicating that these immunological and 
neurochemical factors should not be used to detect the amount of pain that patients 
experience, but rather be viewed as biomarkers to distinguish NP from other types of 
pain. 
 In conclusion this study shows a specific series of changes in the concentrations of 
immunological and neurochemical factors in blood and CSF that as a whole can be 
used as a biomarker set to distinguish NP from other types of pain in patients with 
FBSS (Figure 3). In blood these changes consist of elevated concentrations of TNF-α, 
GABA and NPY and decreased concentrations of BDNF and CGRP-α, consequently 
favoring inflammation and jeopardizing neuroprotection. In the CSF, elevated TNF-α 
concentrations have been detected. Moreover, BDNF and CGRP-α concentrations in 
the blood increase with successful SCS thereby allowing for monitoring effects of SCS. 
 
 
Figure 3. Blood and CSF concentrations of factors associated with NP. Dotted lines indicate
assumed interactions. 
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CHAPTER 8 
General discussion and recommendations 
for future research 
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In this PhD thesis, possible new targets and treatments for neuropathic pain have been 
investigated. The research questions we addressed were: 
• What is the role of BDNF in animals suffering from neuropathic pain? 
• Do amitriptyline, gabapentin and minocycline reduce neuropathic pain behavior in 
a rat chronic constriction injury model via BDNF? 
• Can minocycline and amitriptyline reduce lumbosacral radicular pain in humans? 
• What is the current state of the art concerning occipital neuralgia? 
• Can PRF at the level of the occipital nerves reduce neuropathic pain in occipital 
neuralgia? 
• Can neurotransmitters and other neurochemical messengers be used as biological 
indicators for neuropathic pain? 
Based on our investigations, we offer the following answers to these questions, and 
give recommendations for future research. 
8.1 BDNF plays a pivotal role in the generation of neuropathic pain in 
animal models 
In Chapter 2, we have assessed the role of BDNF in a number of well-studied animal 
models for neuropathic pain research by reviewing the literature, and we have con-
cluded that different lesions give rise to different patterns of BDNF expression at the 
lesion site, in the DRG as well as in the dorsal horn [1]. Even when only one model is 
taken into account, the pattern of BDNF expression clearly depends on the amount of 
damage evoked. The mechanisms by which BDNF generates neuropathic pain are 
various but they all lead to a disinhibition or hyperexcitability of the dorsal horn, 
thereby stimulating nociceptive output from the spinal sensory system. However, the 
common denominator in every model is the fact that BDNF-antagonism, directly by 
scavenging BDNF molecules or reducing BDNF expression or indirectly by TrkB-
receptor antagonism or second messenger inhibition, results in reduced neuropathic 
pain behavior [2-4]. Meanwhile, there is some inconsistency on this issue in the litera-
ture. Conflicting evidence, which suggests an anti-nociceptive role of BDNF, may be the 
result of interspecies differences in the expression of neuropathic pain and of BDNF 
[5]. Furthermore, inconsistency may be caused by intraspecies disparity between male 
and female animals in the expression of BDNF and neuropathic pain. Finally, BDNF has 
a clear dose-dependent effect on neuropathic pain: whereas low doses of exogenously 
administered BDNF can suppress mechanical allodynia, high doses have the opposite 
effect [6]. 
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8.2 BDNF expression is not inhibited by current treatments of neuropathic 
pain, and therefore BDNF represents a new target in the treatment of 
neuropathic pain in humans 
Current treatment of neuropathic pain aims at increasing central nervous system 
serotonin and norepinephrine levels by administering tricyclic antidepressants such as 
amitriptyline and selective norepinephrine reuptake inhibitors or at decreasing gluta-
mate and substance P release by blocking the α2-δ subunit of voltage-dependent 
calcium channels with anticonvulsant drugs such as gabapentin. 
 In Chapter 3, we have demonstrated that minocycline and amitriptyline but not 
gabapentin reduce neuropathic pain behavior in a rodent model of neuropathic pain 
when administered post-injury. Moreover, minocycline appeared to be the only drug 
that reduced spinal expression of BDNF. Figure 1 provides an overview of mechanisms 
implicated in the generation of neuropathic pain that are influenced by minocycline in 
the dorsal horn. From this figure it becomes clear that multiple pain signals converge 
on microglia while, in turn, the output signal from this microglia is rather limited, with 
BDNF as the most important downstream effector. Minocycline exerts several inhibito-
ry actions on multiple pathways in spinal microglia and dorsal horn neurons, thereby 
causing reduced BDNF expression on one hand and attenuation of downstream effects 
of BDNF on the other. Consequently, it can be concluded that minocycline meets the 
criteria needed for a drug to be used in the treatment of neuropathic pain in humans. 
There is, however, a therapeutic window wherein minocycline should be administered 
post-injury in order to be effective [7, 8]. 
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Figure 1. The inhibitory effects of minocycline on different pathways contributing to neuropathic pain. NOS:
nitric oxide synthase; TLR4: toll-like receptor 4; CCL2: CC chemokine ligand 2; GRK2: G protein-coupled 
receptor kinase 2; CREB: cyclic AMP response element binding protein; IL18: interleukin 18; IL1β: interleukin 
1β; p38-MAPK: p38 mitogen-activated protein kinase; P2X4: purinergic receptor; KCC2: potassium chloride 
exporter 2; TrkB: tyrosine kinase receptor B; mGluR5: metabotrope glutamate receptor 5; ATP: adenosine-5’-
triphosphate; VDCC: voltage-dependent calcium channel; TNFα: tumor necrosis factor α, INFγ: interferon γ; 
Glu: glutamate; SP: substance P; CGRP: calcitonin gene-related peptide; NMDA: N-methyl-D-aspartate 
receptor; AMPA: α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor; NK1: neurokinin receptor 
1; NKA: neurokinin A; Nav 1.3: voltage dependent sodium channel 1.3. Illustration: Rogier Trompert, Medical 
Art. 
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8.3 Minocycline is a therapeutic agent for lumbosacral radicular 
neuropathic pain in humans 
The first animal study concerning minocycline and neuropathic pain treatment was 
published in 2003 [9]. However, only recently also human studies were undertaken to 
investigate this drug’s applicability in this condition. Conversely, the use of amitripty-
line [10] and gabapentin [11] in neuropathic pain treatment was first reported in 
humans with publications of animal studies exploring their molecular functioning 
following 26 years [12] and 1 year [13] later, respectively. 
 In Chapter 4 we present evidence that minocycline provides short-term improve-
ment of subacute lumbosacral radicular neuropathic pain with limited side-effects. 
Similar findings were noted in patients suffering from diabetic polyneuropathy [14]. 
Although a small randomized clinical trial (RCT) with the specific p38 MAPK inhibitor 
dilmapimod [15] showed promising results in patients with nerve injury, the results 
could not be repeated in a larger RCT with a similar compound (losmapimod) [16]. A 
chemokine receptor 2 antagonist, equally failed to show superiority over placebo in 
patients with posttraumatic neuralgia [17]. Therefore, p38 MAPK- and CCL2-inhibition 
are not the only mechanisms by which minocycline attenuates neuropathic pain in 
humans. The simultaneous action of minocycline on multiple intracellular pathways 
leading to reduced BDNF expression seems to determine the global clinical outcome, 
rather than a specific action of BDNF on a single enzyme or compound. Moreover, 
animal studies have revealed that the release of BDNF is biphasic. Initially, BDNF 
release takes place from a pre-existing cytoplasmic pool, after which newly synthesized 
BDNF is released via p38 MAPK- or CCR2/CCL2-dependent pathways [18]. Therefore, 
p38 MAPK- and CCR2/CCL2-inhibitors are unlikely to inhibit the initial phase of BDNF 
release and since BDNF is known to have an autocrine effect [19], p38 MAPK inhibitors 
may be unable to reverse the pathogenesis of neuropathic pain once this has started. 
8.4 There are well-established diagnostic criteria for occipital neuralgia but 
no gold standard for its treatment 
In Chapter 5 the current literature concerning the epidemiology, diagnosis and therapy 
of occipital neuralgia has been reviewed. The International Headache Society defined 
occipital neuralgia as a paroxysmal shooting or stabbing pain in the dermatomes of the 
nervus occipitalis major or nervus occipitalis minor associated with hypo- or dysesthe-
sia in the area of the nervus occipitalis major or minor as well as with tenderness to 
pressure over the course of the nervus occipitalis major or minor. This clinical presen-
tation combined with a temporary improvement after a diagnostic block of the nervus 
occipitalis major and/or minor confirms the diagnosis [20]. Several therapies for 
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occipital neuralgia have been propagated such as infiltrations with corticosteroid or 
with Botulinum toxin A, PRF of the occipital nerves or the DRG of C2, and subcutane-
ous neurostimulation [21-25]. The quality of the evidence concerning the treatment of 
occipital neuralgia was graded by the system proposed by Guyatt et al. [26] and 
adapted by van Kleef et al. [27] which resulted in the following conclusions and rec-
ommendations: 
• A single infiltration of the nervus occipitalis major with local anesthetic and corti-
coids may be considered for the treatment of occipital neuralgia. 
• The results of infiltrations with Botulinum toxin A are contradictory. 
• PRF of the occipital nerves should be considered if infiltration with local anesthetic 
and corticoids fail to provide sufficient pain relief. 
• PRF of the DRG of C2 is only recommended in a clinical trial setting. 
• Subcutaneous nerve stimulation can be considered in severe disabling pain that is 
unresponsive to other treatments. 
In the absence of trials that compare these different treatments, it appears that there 
is no identifiable gold standard for the treatment of occipital neuralgia. 
8.5 PRF of peripheral nerves is an effective treatment of neuropathic pain 
In Chapter 6 we demonstrate long-term pain relief of occipital neuralgia after PRF of 
the occipital nerves. Moreover, in a follow-up study we have built on these findings 
and discovered that PRF not only reduces pain intensity but also neuropathic symp-
toms. Eight weeks after PRF treatment of the occipital nerves, the VAS and DN4 scores 
were significantly reduced to baseline (7.6±0.4 vs. 4.5±0.6, P≤0.001 and 4.5±0.4 vs. 
3.1±0.5, P≤0.001, respectively; P. Vanelderen, unpublished results). Recent investiga-
tions show that a traumatic inciting event, low diagnostic block volumes and employ-
ment of several bouts of PRF correlate with a positive outcome after PRF of the occipi-
tal nerves [28]. Also recently, the first randomized, double-blind, placebo-controlled 
trial involving PRF of the peripheral intercostal nerves was performed to treat neuro-
pathic pain in patients with post-zoster neuralgia [29]. PRF was associated with lower 
pain scores and reduced need for analgesics 6 months after therapy. The mode of 
action of PRF still needs to be clarified. Whereas many investigations have been per-
formed on the effects of PRF on the central nervous system, animal research data 
concerning PRF on peripheral nerves are sparse. After PRF, Erdine et al. [30] and 
Protasoni et al. [31] found an acute as well as a prolonged increase in smooth endo-
plasmic reticulum in DRG neurons with swollen cisternae and numerous vacuoles in 
ganglion cells. Furthermore, myelinated axons revealed pathological features such as 
aberrant myelin coverage. Also after PRF, pain processing neurons in the DRG showed 
upregulation of c-Fos [32, 33] and ATF-3 [34], markers for neuronal activity and cellular 
stress. All these data suggest that PRF applied at the level of the DRG induces stress or 
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injury in nociceptive neurons thereby leading to reduced synaptic transmission [35]. 
Spinal descending adrenergic and serotonergic pathways as well as the endogenous 
opioid system seem to play important roles in the analgesic action of PRF [36, 37]. In a 
rodent inflammatory pain model, PRF applied to the sciatic nerve was unable to 
attenuate mechanical hyperalgesia, as opposed to PRF administered to the DRG [38]. 
However, in a rodent model of neuropathic pain (spared nerve injury) PRF applied at 
the sciatic nerve reversed mechanical allodynia within 24 hours together with a down-
regulation of TNF-α and IL-6 in the sciatic nerve and DRG and an up-regulation of the 
GABAB-R1 and the 5-HT3 receptor as well as of Na+/K+-ATPase in the DRG [39]. We may 
conclude that in neuropathic pain states, PRF applied at the peripheral nerve and DRG 
reduces the expression of pro-inflammatory cytokines and blocks synaptic nociceptive 
transmission, similarly to what is seen with microglial inhibition and BDNF antagonism. 
8.6 BDNF, CGRP-α, TNF-α and NPY may serve as biological indicators for 
neuropathic pain 
In Chapter 7 we have assessed the concentrations in the blood and in the CSF of key 
molecules known to participate in the generation and maintenance of neuropathic 
pain of patients suffering from chronic lumbosacral radicular neuropathic pain caused 
by failed back surgery syndrome. We found decreased serum concentrations of BDNF 
and CGRP-α and an increased concentration of TNF-α in the blood and CSF as well as 
an increased concentration of NPY in serum and plasma and an increased concentra-
tion of GABA in plasma. Moreover, successful treatment by spinal cord stimulation 
increased serum concentrations of BDNF and CGRP-α. The low serum BDNF concentra-
tions in these patients may have resulted from impaired BDNF release from platelets 
and/or from depleted platelet BDNF-stores. We specifically searched for biomarkers to 
differentiate neuropathic pain from other types of pain. Since the expression of pain is 
not only the result of nociception but also of a myriad of biopsychosocial factors that 
influence pain perception, biomarkers will hardly ever help to predict the pain a 
patient will experience in an accurate quantitative way, but they can certainly help us 
to distinguish different types of pain thus allowing for better targeted therapies. Since 
neuropathic pain affects neurochemical messenger profiles that themselves change 
over time as well, we should consider multiple candidate substances at multiple time 
points during treatment. 
8.7 Recommendations for future research 
Up to now, relatively little attention has been paid to differences in neuropathic pain 
mechanisms in animal models with regard to species and gender. Also, animal studies 
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in neuropathic pain research often use a pre-emptive study design, a paradigm that 
hardly reflects the clinical setting where patients seek medical advice after pain has 
arisen. Therefore, we recommend that future research will take into account species 
and gender differences, and involves post-injury drug administration to better mimic 
the clinical situation. 
 Forthcoming research in which therapy of neuropathic pain with minocycline is 
investigated should use larger patient cohorts, different etiologies of neuropathic pain 
and longer follow-up periods to determine the decisive place of this drug in the treat-
ment of neuropathic pain. Also, since lumbosacral radicular pain is far more prevalent 
than postherpetic neuropathic pain and diabetic polyneuropathy, research on the 
pharmacotherapy of this condition deserves increased attention. 
 There is a need for trials that compare the effects of PRF at the level of peripheral 
nerves with those of other treatments of peripheral neuropathic pain in order to 
establish good treatment algorithms for this condition. In view of the similarities 
between microglial inhibition and the effect of PRF, future studies concerning the 
mode of action of PRF should focus on the modulation of microglial activity and BDNF 
expression. 
 In future biomarker research there should be adequate matching of patients and 
controls because in healthy controls significant variations in the concentration of such 
substances have been demonstrated with regard to age, gender and body weight, and 
diurnal and seasonal variation [40-42]. 
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The aim of this thesis research was to investigate new targets and treatments for 
neuropathic pain. 
 
In Chapter 1 we provide a brief overview of the definition, epidemiology and patho-
physiology of pain in general and neuropathic pain in particular. Next, the different 
neuropathic pain syndromes and their treatments that we studied in this thesis are 
discussed with a special emphasis on potentially new drugs. 
 
In Chapter 2 we summarize the role of the growth factor BDNF in four animal models 
of neuropathic pain (chronic constriction and transection of the sciatic and spinal 
nerves). BDNF is involved in the generation and maintenance of neuropathic pain in 
each of the above mentioned animal models. Moreover, inhibition of BDNF reduces 
neuropathic pain behavior in these animal models, thus making this growth factor a 
new target for the treatment of neuropathic pain. 
 
The effect of amitriptyline and gabapentin, both first-line treatments for neuropathic 
pain, and minocycline, a tetracycline antibiotic drug and microglial inhibitor, in a rat 
chronic constriction injury of the sciatic nerve is presented in Chapter 3. Amitriptyline 
and minocycline both reduced neuropathic pain as opposed to gabapentin, which 
showed no effect. Moreover, minocycline was the only drug that reduced spinal BDNF 
expression. Therefore, minocycline can be a valuable new treatment for neuropathic 
pain in humans. 
 
The findings of our animal study were translated into a clinical trial in Chapter 4 by 
studying the effect of minocycline, amitriptyline and placebo in patients suffering from 
lumbosacral radicular pain. Both minocycline and amitriptyline reduced radicular pain 
compared to placebo. Moreover, patients treated with minocycline experienced less 
side-effects. 
 
In Chapter 5 we reviewed the literature concerning occipital neuralgia and proposed 
evidence-based treatment guidelines according to the current state of the art. 
 
The long-term effect of PRF on occipital neuralgia was investigated in Chapter 6. PRF 
significantly reduced pain intensity and the need for analgesics, while improving 
quality of life of patients. 
 
The usefulness as a biological indicator of several neurochemical messengers involved 
in the generation and maintenance of neuropathic pain in patients suffering from 
chronic lumbosacral radicular pain was investigated in Chapter 7. We found decreased 
blood concentrations of BDNF, CGRP-α and increased concentrations of TNF-α in the 
blood and CSF as well as increased blood concentrations of NPY and GABA. Moreover, 
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successful treatment with spinal cord stimulation restored blood concentrations of 
BDNF and CGRP-α. 
 
In Chapter 8 we discussed the results of the thesis research in a broad and integrated 
context and made recommendations for future research into the origin(s) and therapy 
of neuropathic pain in animals and humans. 
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Het doel van dit promotieonderzoek was om nieuwe aangrijpingspunten en behande-
lingen van neuropathische pijn te vinden. 
 
Hoofdstuk 1 behandelt op beknopte wijze de definitie, epidemiologie, pathogenese en 
pathofysiologie van pijn in het algemeen en van neuropathische pijn in het bijzonder. 
Voorts worden de verschillende neuropathische aandoeningen en hun behandelingen 
beschreven die in dit onderzoek aan de orde zijn gekomen, met bijzondere aandacht 
voor aangrijpingspunten voor potentiële nieuwe geneesmiddelen. 
 
De rol van de groeifactor BDNF in vier verschillende proefdiermodellen van neuropa-
thische pijn (chronische constrictie c.q. doorsnijding van de nervus ischiadicus of van 
spinale zenuwen) wordt beschreven in Hoofdstuk 2. BDNF blijkt betrokken te zijn bij 
het ontstaan en aanhouden van neuropathische pijn in ieder beschreven diermodel. 
Bovendien neemt het neuropathische pijngedrag bij de proefdieren af wanneer de 
neuronale afgifte van BDNF wordt geremd. Hierdoor vormt BDNF een nieuw aangrij-
pingspunt voor de behandeling van neuropathische pijn. 
 
In een chronisch constrictie model van de n. ischiadicus van de rat zijn de anti-
neuropathische effecten van het tetracycline antibioticum en remmer van microglia, 
minocycline, vergeleken met die van twee huidige geneesmiddelen tegen neuropathi-
sche pijn, amitriptyline en gabapentine (Hoofdstuk 3). Zowel amitriptyline als minocy-
cline verminderden het neuropathische pijngedrag bij de proefdieren. Dit was in 
tegenstelling tot gabapentine, dat geen effect op dat pijngedrag vertoonde. Bovendien 
bleek alleen minocycline in staat om de biosynthese van BDNF in het ruggenmerg te 
onderdrukken. Daarom kan minocycline beschouwd worden als een veelbelovend 
nieuw geneesmiddel voor de behandeling van neuropathische pijn bij mensen. 
 
In Hoofdstuk 4 wordt beschreven hoe de resultaten van het bovengenoemde dieron-
derzoek zijn toegepast in een klinische studie waarbij patiënten die lijden aan lumbos-
acrale radiculaire pijn behandeld werden met amitriptyline, minocycline of een place-
bo. Zowel minocycline als amitriptyline verminderden de intensiteit van de 
neuropathische pijn, maar patiënten die behandeld waren met minocycline ondervon-
den minder bijwerkingen. 
 
Hoofdstuk 5 betreft een literatuurstudie naar de behandeling van occipitalis neuralgie. 
Op basis hiervan zijn een aantal richtlijnen geformuleerd voor de behandeling van deze 
aandoening. 
 
In Hoofdstuk 6 wordt aangetoond dat gepulseerde radiofrequente therapie van de 
occipitale zenuwen leidt tot een daling van de pijnintensiteit en het medicijngebruik bij 
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patiënten die lijden aan occipitalis neuralgie. Bovendien trad er een belangrijke verbe-
tering van de levenskwaliteit op. 
 
Bij patiënten met chronische lumbosacrale radiculaire pijn is van een aantal belangrijke 
zenuwcelmoleculen nagegaan of zij gebruikt zouden kunnen worden als ‘biomarker’ 
voor pathofysiologische processen die betrokken zijn bij het ontstaan en/of aanhou-
den van neuropathische pijn (Hoofdstuk 7). Bij deze patiënten werd een daling waar-
genomen van de concentraties van BDNF en het neuropeptide CGRP-α in het bloed en 
een stijging van de concentratie van de tumor necrosefactor TNF-α in het bloed en in 
het cerebrospinaal vocht evenals een stijging van de concentraties van het neuropep-
tide Y en de neurotransmitter GABA in het bloed. Door behandeling met dorsale streng 
stimulatie van het ruggenmerg konden de bloedconcentraties van BDNF en CGRP-α 
weer teruggebracht worden naar hun normale niveaus. 
 
In Hoofdstuk 8 zijn de resultaten van dit onderzoek in een brede context geplaatst en 
worden tot slot aanbevelingen gedaan voor verder onderzoek naar het ontstaan en de 
behandeling van neuropathische aandoeningen bij dier en mens. 
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